Studies on using data-driven decision support systems to improve personalized medicine processes by Cameron, Kellas Ross
Boston University
OpenBU http://open.bu.edu
Theses & Dissertations Boston University Theses & Dissertations
2018
Studies on using data-driven
decision support systems to
improve personalized medicine
processes
https://hdl.handle.net/2144/30452
Boston University
BOSTON UNIVERSITY 
 
QUESTROM SCHOOL OF BUSINESS 
 
 
 
 
 
Dissertation 
 
 
 
 
 
STUDIES ON USING DATA-DRIVEN DECISION SUPPORT SYSTEMS 
 
TO IMPROVE PERSONALIZED MEDICINE PROCESSES 
 
 
 
 
by 
 
 
 
 
KELLAS ROSS CAMERON 
 
S.B., S.B., Massachusetts Institute of Technology, 2010 
M.S.E., University of Texas at Austin, 2011 
M.Eng., Boston University, 2013 
 
 
 
 
 
 
Submitted in partial fulfillment of the 
 
requirements for the degree of 
 
Doctor of Philosophy 
 
2018  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© 2018 by 
 KELLAS ROSS CAMERON 
 All rights reserved  
Approved by 
 
 
 
 
 
 
 
First Reader   
 Nitin R. Joglekar, Ph.D. 
 Dean’s Research Scholar 
 Associate Professor of Operations and Technology Management 
 
 
 
 
Second Reader   
 Janelle Heineke, D.B.A. 
 Everett W. Lord Distinguished Faculty Scholar 
 Professor and Chair of Operations and Technology Management 
 
 
 
 
Third Reader   
 Nachiketa Sahoo, Ph.D. 
 Assistant Professor of Information Systems 
 
 
 
 
Fourth Reader   
 Jugnu Jain, Ph.D. 
 Chief Executive Officer 
 Sapien Biosciences 
 
		 iv 
DEDICATION 
 
 
 
 
For my parents, Kim and Kellas Cameron, and my husband, Jayson. 
  
		 v 
ACKNOWLEDGMENTS 
 As I contemplate completing what I have affectionately termed “24th Grade,” I 
have realized that I would not have been able to accomplish all that I have done during 
my twelve years of higher education without the help of some truly exceptional 
people.   
 I moved to the United States twelve years ago, only two days after receiving 
my A-Level results, and though the journey has been tough, it has been incredibly 
worth it.  I couldn’t have made this journey without the support and encouragement of 
my mother, Kim Cameron.  She is by far the strongest, smartest, and most resilient 
person I have ever met, or will ever meet.  As far back as I can remember, she has 
sacrificed everything in order to provide me with the best life and the best education 
possible.  She gave me every opportunity that a person could dream of. I know how 
difficult it was for her when I left the United Kingdom in order to go to MIT, but over 
these twelve years, her love and support has been unwavering.  Thank you, Mam, for 
everything, and I hope I can return the favor soon. 
 Next, I want to thank my father, Kellas Robert Cameron, for being my 
champion.  I can’t imagine that it was easy being a normal person living in a house full 
of nerds, but you gave me a guide post for understanding what it meant to be a good, 
honest, and caring person, as you’ve always been a shining example. Dad, you’ve 
always been in my corner, and you don’t know how much I appreciate that. 
 Of course, a large thank you to my husband, Jayson, whose has borne the brunt 
of the majority of stresses that the doctoral program has thrown at me, and yet you still 
		 vi 
were willing to marry me.  I know it is never going to be simple being the partner of 
an academic, but I couldn’t imagine living this life without you.  You have made 
everyday the best it can be, I love you and I cannot wait for us to start our new life in 
Tampa. 
 To my advisor, Nitin Joglekar, who always kept pushing in the right direction, 
thank you for giving me some of the soundest advice a student could ask for.  Without 
you, I may never have entered the PhD program, and I definitely wouldn’t be leaving 
it with as much success as I have. 
 To Janelle Heineke, our department head, who has been a combination of my 
academic rock, my sanity, and my friend, depending on what the situation called for.  I 
am forever grateful for your help and guidance, and it will be missed. 
 To Nachi Sahoo, who never let me get away with the simple approach, I will 
always appreciate how much you taught me, especially when you didn’t have to. 
 To Jugnu Jain, JK Srinivasan, and Lakshmipathi Khandrika, without whom a 
bulk of this research would not have been possible, I thank you all for the gift of your 
time and data, which I know are both very valuable, and for immersing me in the 
healthcare domain in a way that would have been impossible without you. 
 To Carrie Queenan, thank you for being a friend and an amazing co-author, 
you made writing my first paper such a delight, and it was due to that experience that I 
decided to pursue the study of healthcare operations. Thank you for being a mentor 
from a far!   
 To the faculty and staff of Questrom – Anita Tucker, Robb Dixon, Jillian 
		 vii 
Berry-Jaeker, Marcus Bellamy, Jay Kim, Paul Morrison, Barry Kadets, Mary 
McDonough, Marta McManus, Keane Wimberley, and Patty Caffrey – thank you for 
all your help and guidance. 
 Lastly, a thank you (and a congratulations in their own right) to my fellow PhD 
students – Emre Guzelsu, Alf Wang, Jon Beebe, Sarah Zheng, Brad Lee, and Elnaz 
Karimi – you’re advice, support, and encouragement will be missed as I make the 
move from Questrom to Muma. 
 Thank you, everyone!   
		 viii 
STUDIES ON USING DATA-DRIVEN DECISION SUPPORT SYSTEMS 
 
TO IMPROVE PERSONALIZED MEDICINE PROCESSES 
 
KELLAS ROSS CAMERON 
Boston University Questrom School of Business, 2018 
Major Professor: Nitin R. Joglekar, Ph.D., Dean’s Research Scholar, Associate 
Professor of Operations and Technology Management 
 
ABSTRACT 
 This dissertation looks at how new sources of information should be 
incorporated into medical decision-making processes to improve patient outcomes and 
reduce costs. There are three fundamental challenges that must be overcome to 
effectively use personalized medicine, we need to understand: 1) how best to 
appropriately designate which patients will receive the greatest value from these 
processes; 2) how physicians and caregivers interpret additional patient-specific 
information and how that affects their decision-making processes; and finally, (3) how 
to account for a patient’s ability to engage in their own healthcare decisions. 
 The first study looks at how we can infer which patients will receive the most 
value from genomic testing.  The difficult statistical problem is how to separate the 
distribution of patients, based on ex-ante factors, to identify the best candidates for 
personalized testing. A model was constructed to infer a healthcare provider’s decision 
on whether this test would provide beneficial information in selecting a patient’s 
medication. Model analysis shows that healthcare providers’ primary focus is to 
maximize patient health outcomes while considering the impact the patient’s economic 
welfare.  
		 ix 
 The second study focuses on understanding how technology-enabled continuity 
of care (TECC) for Chronic Obstructive Pulmonary Disease (COPD) and Congestive 
Heart Failure (CHF) patients can be utilized to improve patient engagement, measured 
in terms of patient activation.  We shed light on the fact that different types of patients 
garnered different levels of value from the use of TECC.  
 The third study looks at how data-driven decision support systems can allow 
physicians to more accurately understand which patients are at high-risk of 
readmission. We look at how we can use available patient-specific information for 
patients admitted with CHF to more accurately identify which patients are most likely 
to be readmitted, and also why – whether for condition-related reasons versus for non-
related reasons, allowing physicians to suggest different patient-specific readmission 
prevention strategies. 
 Taken together, these three studies allow us to build a robust theory to tackle 
these challenges, both operational and policy-related, that need to be addressed for 
physicians to take advantage of the growing availability of patient-specific information 
to improve personalized medication processes. 
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CHAPTER ONE: INTRODUCTION 
In the world of operations management and information systems, we are 
immersed in the ever-present fact that we live in a world where we always have data at 
our fingertips.  Not only do we have access to great volumes of information, but the 
fidelity of that data has also increased over the past five years. 
This is especially true when it comes to the field of Healthcare Operations 
Management.  The availability of patient-specific information has allowed for the 
creation of data-driven decision support systems, which are where data are utilized in 
order to improve or assist with analyses and decision-making processes.  The importance 
of using these decision support systems to aid physicians in making important clinical 
decisions is particularly important when it comes to the use of personalized medicine 
processes. 
Personalized medicine is defined by the American Medical Association as 
“Healthcare that is informed by each person’s unique clinical, genetic, and environmental 
information.”  Understandably, therefore, from a process point of view, it becomes 
increasingly more important for us to understand how to effectively use the wealth of the 
now-available patient-specific information, if we wish to aid physicians in making 
personalized medicine decisions.   
In the domain of healthcare, there are a number broader issues when it comes to 
the use of personalized medicine processes that we need to overcome through the use of 
these data-driven decision making tools.  As with any new technology, there is an 
uncertain clinical value when it comes to their use by both the provider, and also the 
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patient, which has led to a lower rate of adoption of personalized medicine processes.  
However, this does not detract from a preference at a healthcare policy level to increase 
the use of personalized medicine in order for healthcare providers to shift away from 
viewing patients as a homogeneous population, with all the problems that entails. 
We are therefore at a point where operations management and information 
systems are truly provide value when it comes to solving these problems.  The work in 
this dissertation derives from a space in the operations management literature where we 
can develop tools that can minimize these above challenges and complications.  Our field 
allows us to bring to the healthcare decision-making domain the ability to incorporate 
patient and provider learning, the methods to utilize predictive and prescriptive analytic 
techniques, and how to effectively use all that these patient-specific data can offer the 
field of personalized medicine processes. 
This dissertation addresses three operational solutions to different challenges 
faced when utilizing data-driven decision support systems to improve personalized 
medicine processes: 
1. In the first study of this dissertation, we create a systematic understanding 
of how we can ascertain how to go about discovering the patient-specific 
value provided by personalized medicine processes, which allows us to 
the remove uncertainty concerning their clinical value. 
2. In the second study of this dissertation, we learn how patients engage 
with their own healthcare, and how this ability affects their ability to 
make their own medical decisions. 
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3. In the third conceptual study of this dissertation, we look to understand 
how healthcare providers interpret additional patient specific data when it 
comes to their decision processes.  It is important for us in the area of 
decision sciences to create models that physicians can understand and 
utilize effectively, if we wish to see an increase in the adoption of 
decision support systems.   
These three studies provide a multi-faceted method of understanding of how the 
fields of operations management and information systems can be be used to overcome 
challenges and create data-driven decision support systems to improve the quality and 
utilization of personalized medicine processes.
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CHAPTER TWO:  HOW MUCH IS THE VALUE OF GENOMIC TEST 
INFORMATION? EVIDENCE FROM POST-CARDIAC STENT CARE 
DECISIONS 
Introduction 
In healthcare, current treatment and medication strategies can be ineffective for 
40% (e.g., for depression, asthma, and cardiac conditions) to over 70% (e.g., for 
oncological conditions, and Alzheimer’s disease) patients (Food and Administration 
2013). Thus, physicians often need to see the patients repeatedly to adjust their 
medications, in a trial-and-error fashion, which results in inefficient treatment and 
significant costs for the patient, the provider, and insurance organizations. To address this 
inefficiency, the healthcare industry has been moving toward more personalized 
approaches aided by advanced genetic and molecular diagnosis techniques (Xie and 
Frueh 2005). This is often called Personalized Medicine because such treatment “is 
informed by each person’s unique clinical, genetic, and environmental information” 
(Goldberger and Buxton 2013). 
There are two barriers to the adoption of new diagnostic technologies for 
personalized medicine. First, these technologies can be expensive and unaffordable for 
many patients without adequate medical insurance or resources. Second, the information 
provided by such tests may not always be clinically meaningful, i.e., make a difference in 
the physician’s treatment decision. Physicians consider these factors — costs and value 
of the information from the test — when making testing and treatment recommendations 
(NIH 2017). If the patients who are likely to benefit the most from advanced diagnostic 
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techniques can be identified, then it can help the physicians’ decisions, raise the efficacy 
of the treatments, hasten the adoption of the budding genomic and molecular 
technologies, and improve overall health outcomes. 
One key example context where personalized medicine could be particularly 
effective is in patient care following cardiac stent surgeries. Over one million U.S. 
patients receive some form of vascular stent each year (Loehrke et al. 2013). In such a 
surgery, a cardiologist implants a tubular device (a stent) to open a patient’s artery that 
has been blocked (Levine et al. 2011). However, after the procedure, the patient faces a 
higher risk of blood clotting (thrombosis) in the stented artery, which could lead to a 
stroke, and potentially, death. To manage this risk, the physician typically prescribes an 
anti-clotting medication for 3 to 12 months post surgery. Here lies the opportunity for 
personalized medication. 
The two predominant anti-clotting medications in use today — Clopidogrel and 
Ticagrelor — have different risk profiles, different mechanisms to prevent clotting, and 
different monetary costs. For Clopidogrel to be effective, a certain genotype must be 
present. Ticagrelor does not depend on the genotype and has a lower risk of clotting, but 
has a greater risk of causing bleeding from the site where the stent is placed. A new 
genomic test, MyPLATELET, can reveal the genotype of the patient and enable the 
physician to predict a patient’s likely response to Clopidogrel. However, the costs of 
these diagnostic tests (approximately 6,500 INR, or US$ 100) can be prohibitive for some 
patients in our study context of cardiac stent surgery in India - especially in the absence 
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of any ex-ante guidance on how medically valuable the test information will be in their 
particular cases. 
Is it possible to estimate the value of the diagnostic test ex-ante? Such estimates 
can help patients and physicians make better-informed testing decisions for individual 
patient cases. At the patient population level, by preferentially routing the patients who 
will benefit the most to personalized treatment regimens based on new genomic and 
molecular testing technologies, healthcare providers can reduce the total population 
disutility (the sum of suffering from poor health outcomes and the financial cost of the 
treatment).  
We posit that a data-driven approach could be used to estimate ex-ante the 
medical value of the diagnostic test data based on the patient’s physical and health 
attributes. We contribute such an approach by developing a structural econometric model 
of how physicians weigh the risk and the disutility of different health outcomes when 
choosing an anti-clotting medication for a given patient. We estimate this model from a 
dataset containing medical and economic attributes on 427 patients in India who 
underwent cardiac stent surgery to obtain insight into how patients’ diverse medical and 
economic attributes affect physicians’ medication decisions. We evaluate the proposed 
model using data from a matched group of patients in which only one subgroup received 
genomic testing and find that it can better estimate the effect of the test on change in 
medication decision than the alternative classifiers, such as, Support Vector Machine, 
Decision Tree, and Logistic Regression can. Finally, through a set of policy simulations, 
we show that the proposed model can be used to reduce the patients’ disutility and 
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improve the adoption of the genomic test enabling the patients who need the test the most 
to benefit from it sooner. 
Literature Background 
A long stream of research in management sciences has studied the impact and the 
value of information — defined as the decision maker’s payoff with and without 
particular information — under various contexts. Researchers have studied the value of 
waiting for additional information, efficient experiments for maximum information, 
information value of competition, managerial-flexibility that asymmetric information 
affords, and the value of sharing information across supply chain (for a review, please see 
Banker and Kauffman (2004)). Follow on work has examined the value of multi-site 
information for eCRM models (Padmanabhan et al. 2006) and inter-functional inter-
organizational coordination using information systems (Bharadwaj et al. 2007). 
Application of these ideas to the healthcare domain requires a consideration of 
pharmacoeconomics (Claxton and Sculpher 2006) — comparative evaluation of 
treatments taking into account the monetary costs and the resultant quality of life — 
wherein the conceptualization of value must address policy issues (Porter 2010). Hence, 
we draw upon two literature streams to set up our study: the healthcare information 
system literature, particularly, on data-driven decision making; and the health policy 
literature on personalized medicine. 
Data-driven Decision Making using Health Information System  
Increasing number of management sciences methods have made their way into healthcare 
practices in recent years. Many researchers have brought their in-depth disciplinary 
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knowledge to bear on vexing healthcare problems. They have studied the adoption of 
health information technologies, impact of use of information systems on medical 
outcomes, differing usage of health information technologies by personnel in different 
roles, the privacy implications of personal health records, etc. At the same time, several 
promising directions for future research have been identified. Prominent of them are 
developing predictive models to learn from available health records for enabling more 
personalized care and the use of genetics-driven personalized medicine (Agarwal et al. 
2010, Fichman et al. 2011).  
While adoption of health information technology itself can improve the quality of 
care and efficiency, the data trail created by such a system enables analytics for the next 
order of benefits. Many researchers in Information Systems discipline have taken this 
opportunity to propose statistical and machine learning models to predict health 
outcomes, which may be used to make ex-ante decisions to improve care. For example, 
Bardhan et al. (2015) have developed a statistical model to predict the propensity and 
timing of readmission of patients who have been diagnosed with congestive heart failure. 
Such a model may enable a hospital to identify patients at greater risk and provide 
preventive care. In another study focusing on onset of cardiac arrest, Somanchi et al. 
(2015) have shown that using patients’ demographic information, hospitalization history, 
vitals, and lab measurements — all the variables that are part of modern electronic 
medical records — one can use a classifier, such as a Support Vector Machine, to 
accurately predict if a patient will go into cardiac arrest. Lin et al. (2017) have developed 
a predictive model based on Bayesian multitask learning approach to predict multiple 
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adverse health events that can occur for patients with chronic conditions. They have 
applied their model to predict the onset of stroke, acute myocardial infraction, and acute 
kidney failure for diabetic patients.  Gartner et al. (2015) have taken the predictive 
models a step further by using the predictions to optimize resource allocation in hospital 
inpatient settings. In summary, these publications make the case that if at the time of 
decision making the physicians and other key personnel in the hospital have access to 
accurate predictive tools as part of the health information systems, they can take steps to 
avoid serious outcomes for patients and better utilize providers’ resources. 
While many popular models can be helpful in predicting health outcomes when 
used with rich patient level data that is being collected now, as illustrated by Somanchi et 
al. (2015), there is an opportunity to adapt these techniques, or develop new ones, with 
knowledge from healthcare domain to make them more accurate as well as gather 
important insight into the domains. In fact, due to the higher complexity of the healthcare 
industry compared to other industries the need is even greater to take advantage of 
institutional knowledge in this sector to come up with effective solutions (Agarwal et al. 
2010). Morid et al. (2017) have taken such an approach. They have developed a model 
using temporal feature engineering and change point detection — informed by the 
clinical domain knowledge — for early ICU mortality prediction. They show that the 
model that is developed with guidance from clinical domain knowledge significantly 
outperforms other benchmarks. This is a promising model development paradigm that 
can be taken further. 
Health information systems capture expert-decisions in addition to the patient 
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attributes. When guided by the institutional knowledge, this creates an opportunity to 
learn from the expert-decisions about the context in which those decisions are made. 
Structural econometric framework offers a principled approach to do so by incorporating 
the domain knowledge into a statistical model that can then be used analyze the decisions 
(Huang et al. 2014, Huang et al. 2015). Additionally, structural econometric models 
allow one to estimate the primitives of the decision making, often based on a utility 
maximizing agent’s behavior, that lead to more credible policy implications. This is 
important given the need for research in healthcare that can inform policy debates 
(Agarwal et al. 2010). One example of structural econometric model in healthcare 
information technology setting can be found in Haijing et al. (2017), who have developed 
a model of physician’s decision to adopt a new technology. They find that physicians 
learn from using the new technology as well as from the signals they receive from the 
word-of-mouth of their peers and opinion leaders about new technologies. And as the use 
of technology by the opinion-leader physicians change, so does the adoption of other 
physicians in the population. 
We build on Bardhan et al. (2015), Somanchi et al. (2015), and Lin et al. (2017) 
in health IS literature by bringing in genomic data into the decision model as well as 
structural econometric framework to develop such models in healthcare setting. In our 
decision context, the physician manages competing medical risks (bleeding versus 
clotting) under health and economic cost tradeoffs. In this context, we offer a data-driven 
approach to understand for which types of patients personalized medicine based on new 
genetic- and molecular-diagnostic technologies are likely to improve decisions. 
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Health Policy Issues and Personalized Medicine 
Independent of the research in data-driven decision making using healthcare information 
systems, a growing debate has ensued in the health policy literature about the cost 
effectiveness of new health care technologies in the form of a call for evidence based 
medicine (Sackett et al. 1996). There is a realization that not all new technologies may 
have clinical utility and the technologies that actually affect providers’ decision making 
have the biggest impact on outcome (Dexter et al. 2004, Agarwal et al. 2010, DesRoches 
et al. 2010). Though a patient’s genetic information can enable greater personalization 
leading to improved health outcomes and strong clinical utility these benefits come at a 
typically higher price of testing and the cost of processing the additional information by 
the physician and other healthcare professionals (Conti et al. 2010). When the technology 
is relatively new, evidence of clinical utility is often lacking. As a result, it can be unclear 
whether the potential value from such technologies is worth the cost for a particular 
patient. As Phillips et al. (2014) note: 
One reason why there are relatively few assessments of economic value 
is that many tests do not have widely accepted evidence of clinical 
utility — an impact on medical and nonmedical outcomes — and thus it 
is challenging to conduct definitive cost effectiveness analysis. 
Therefore, for such testing technologies to be effectively adopted, patients and providers 
need guidance as to when the information provided by such tests are going to be 
clinically meaningful. 
Consistent with the literature on multiple outcomes cost effectiveness analysis 
		
12 
(McCaffrey et al. 2015), we have addressed this issue by developing a model of the 
physician that considers disutility from both medical and economic outcomes. This 
approach allows multi-criteria assessment of policy alternatives, such as, (a) testing 
patients when potential value of the information from the test for the patient exceeds the 
economic cost of the test and (b) subsidizing the price of the test for the cost-sensitive 
patients, which can improve overall population welfare. 
Context and Dataset 
The data in this study are drawn from the medical treatments following cardiac 
stent surgery at the Apollo Hospitals, which is the largest hospital network in India. To 
collect these data and to access domain expertise and institutional knowledge, we 
partnered with Sapien Biosciences, a biobank affiliated with Apollo Hospitals. Biobanks 
store and catalog biological specimens such as DNA, plasma, blood, saliva. In this 
section, we first provide some background on the treatment, and then describe the dataset 
used in the study. 
Background on the Treatment 
After cardiac stent surgery, patients take an anti-clotting medication to reduce the risk of 
blood clotting around the stent. Currently, two predominant medications are prescribed: 
the genotype-dependent medication, Clopidogrel, and non-dependent medication, 
Ticagrelor. Clopidogrel requires the patient to have the normal CYP2C19 gene to work. 
When it works, it leads to optimal health outcomes for more patients than Ticagrelor. 
But, without the necessary gene, Clopidogrel could lead to clotting, resulting in 
thrombosis — a serious cardiac event that could result in death (Bonello et al. 2012). 
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Ticagrelor, on the other hand is a newer and more expensive medication that does not 
depend on the gene to be effective. However, it has a higher risk of causing bleeding, 
which is often less serious than thrombosis, but nevertheless, requires immediate 
hospitalization and, potentially, re-stenting (Jonas and Wines 2013).  
Patients can have one of the four genotype groups based on the variants of the 
CYP2C19 gene they carry. These four groups, in the decreasing order of their rate of 
metabolism of Clopidogrel, are labeled Rapid, Good, Intermediate, and Poor (Rath et al. 
2015). For the first two groups (Rapid and Good metabolizers) Clopidogrel is effective. 
For the third and fourth groups — constituting approximately 64% of the patients in India 
— Clopidogrel does not work adequately (Rath et al. 2015). However, it is not possible to 
identify the patient’s genotype group based on the physical and health attributes that are 
typically observable by a physician. However, a new genomic test, MyPLATELET, 
developed by Sapien Biosciences, can determine the CYP2C19 gene variant present and 
consequently predict how well Clopidogrel will work for the patient.  
One criterion for choosing a medication is the patient’s platelet activity level 
(Brar et al. 2011). If the platelet activity level is too low, the patient is at risk of bleeding. 
At the other extreme, if the platelet activity is too high, she is at a risk of thrombosis. In 
choosing the anti-clotting medication, the physician tries to maintain the platelet activity 
level in an intermediate range. The platelet activity level is measured on a scale of 0–1 
using Platelet Reactivity Index (PRI). A PRI in the range of 0.16–0.50 is desirable. In 
addition to the genomic test, MyPLATELET also contains a functional response test that 
can measure the patient’s PRI. 
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Along with our practice partner Sapien Biosciences, we studied the current 
treatment procedure at a few locations of the Apollo Hospitals in India. When patients 
need to undergo PCI and stenting, they are typically given a loading dose of an anti-
clotting medication, either be Clopidogrel or Ticagrelor depending on patient’s medical 
history, existing co-medications, risk factors, socioeconomic status, arrival condition, etc. 
Additionally, post-PCI procedure, the patients are discharged on a maintenance dose of 
Clopidogrel or Ticagrelor based on the above-mentioned factors. During a follow-up 
visit, typically within 30 days of the stent implant surgery, the physician assesses whether 
the initial medication is effective for the patient. If it is not, they typically switch the 
patient to the alternate medication (Figure 1).  
Figure 1: Current Follow-Up Medication Assignment Process 
 
On the one hand, the majority of patients in India are at the risk of suboptimal 
response to Clopidogrel because they do not have the required genotype; on the other, the 
financial cost of the ongoing medication is a significant factor for physicians in deciding 
whether or not to prescribe Ticagrelor — particularly for patients of low socioeconomic 
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status (SES), who typically have limited resources and often do not have medical 
insurance to cover treatment costs. During the data collection period, Ticagrelor was 
approximately 10 times more expensive than Clopidogrel (Theidel et al. 2013). The latter 
has been classified as an essential medication by the Indian government; that is, its price 
is contained by government regulations to keep it affordable for most. The genomic and 
economic factors create incentives for the use of Ticagrelor and Clopidogrel respectively. 
However, the choice between the two could resemble trial-and-error without the genomic 
test. If every patient could be given the MyPLATELET test then much of this uncertainty 
would disappear and the drug-choice process would be simplified (Figure 2). However, 
one deterrent to such an approach is the price of the test. MyPLATELET, a relatively new 
test, is too expensive for many. 
Figure 2: MyPLATELET Follow-Up Medication Assignment Process 
 
Given the heterogeneity of patient conditions, the genotype information revealed 
by the test is not equally valuable for every patient. Patients whose health outcomes are 
more uncertain may benefit more from the additional information from the genomic test. 
For these patients, the price of the test may justify the benefit. 
Data 
We collect data on two groups of patients at Apollo Hospitals in India who underwent 
cardiac stent surgery in 2013–2016. The first group, of 252 patients, was not given the 
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option of and did not receive, the MyPLATELET test (Non-tested group, Figure 1). The 
second group, of 175 patients, is the subset of patients with access to the MyPLATELET 
test who opted-in for the test in consultation with their physician (Tested group, Figure 
2). Because of the lack of access to the test for the first group and the self-selection of the 
test in the second, there could be differences among the patients in the two groups. For 
each patient, we collect demographic information (age, sex, BMI), co-morbidities 
(hypertension, heart disease, diabetes), location of stent (left arterial, right coronary, or 
left circumflex — the most complex procedure), if they had any previous history of 
stenting, and whether they were admitted with angina (a type of chest pain). 
In data from both groups, the initial medication and the type of stent used are 
available as well. There are two types of stents in our dataset: the less expensive bare 
metal stent and the more expensive drug-eluting stent that slowly releases a drug to 
prevent cell proliferation around the location of the stent (Lagerqvist et al. 2007). For 
each type of stent there are subtypes and brands with prices from 10,000 INR to 250,000 
INR (US$ 154 to US$ 3,804) in our dataset. The price of the stent can play a major role 
in the selection process because low socioeconomic-status patients, who typically do not 
have insurance and other forms of resources, can generally afford only the least costly 
bare metal stent. We classified the patients using a stent priced at or below 15,000 INR 
(US$ 230) to be of low socioeconomic-status and the others as high socioeconomic-
status. 
The group that did not get the MyPLATELET test is labeled the Non-tested group. 
For this group we have data on whether the physician changed the medication during the 
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patient’s follow-up visit. For the Tested group, we know the results of their 
MyPLATELET test (the CYP2C19 gene variant and the PRI due to the initial medication) 
along with the clinically recommended follow-up medication after considering the 
genotype and PRI data from the test. Table 1 presents a comparative summary of the 
Tested and Non-tested groups. 
 
Table 1: Summary Statistics of the Tested and Non-tested Groups 
 
Non-Tested 
(%) 
Tested1 
(%)  
Non-Tested 
(%) 
Tested 
(%) 
Demographics Stent Location 
Age (1: > 60) 40.9 50.3 Left Arterial 74.2 71.4 
Sex (1: Male) 81.3 85.1 Left Circumflex 25.4 35.4 
Health Condition Right Coronary 39.3 41.7 
BMI (1: ≥25) 60.7 61.1 Socioeconomic Status 
Angina 85.3 90.9 Low 31.4 16.0 
Previous Stent? 12.7 22.3 High 68.6 84.0 
Drug Eluting Stent2 77.8 96.0 Medication 
Hypertension 52.8 62.3 Clopidogrel Initially3 40.5 33.4 
Heart disease 25.8 36.6 Medication switch was 
recommended 
15.8 28.6 
Diabetes 39.7 48.0 
Note: 1. There were 252 patients in the non-tested group and 175 in the tested group. 2. Those 
who did not get drug-eluting stent got bare metal stent. 3. Those who did not get Clopidogrel got 
Ticagrelor. 
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Model 
Who should we test for genotype? Intuitively, a patient should be tested if 
knowing her genotype would lead to a reduction in her total disutility: the combination of 
the suffering associated with the health outcomes and the economic cost of the treatment. 
In fact, minimizing total patient disutility drives physicians’ medication choices — even 
without genomic testing. Therefore, we might be able to learn how physicians associate 
probabilities of various health outcomes with patient attributes under different 
medications, from their observed choices of medications. 
Consider how the physician decides which of the two medications to prescribe 
during the post-surgical follow-up visit. The physician has the historical, demographic, 
medications, and contra-medications data for each patient. The genotype group 𝐺 and the 
PRI are available only for the Tested group. For the Non-tested group, neither the 
physician nor we knows the 𝐺 or PRI of a specific patient. The physician takes a decision 
to minimize the total expected disutility for the patient given this information. 
When the decisions of the agents, physicians in this case, under uncertainty are 
modeled without direct access to the actual uncertainty present in the agents’ mind, often 
the rational expectation assumption is used (Muth 1961, Lucas 1972, Bhargava and 
Choudhary 2004, Li et al. 2014). This assumption states that on average the agents act as 
if they precisely know some of the underlying mechanisms in the rest of the model. This 
ensures that the model is internally consistent. In our study context, we make two such 
assumptions about the physicians’ behavior:  
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a) The physicians act as if they know the distribution of genotype group 𝐺 to be what is 
present in the population. Rath et al (2015) have measured this to be 𝑃 𝐺 = {0.170, 0.195, 0.470, 0.165} for the Rapid, Normal, Intermediate, and Poor genotype 
groups respectively in the patient population in India. 
b) The physicians act as if they know the distribution of the platelet activity level, 
measured through PRI, as a function of the patient characteristics and the choice of 
medication — the same function that governs the distribution of the observed PRI in 
the Tested patients. 
To construct the model we first define the variable active medication — the 
medication that affects the PRI, or any consequence of the PRI, that is being modeled. 
For the Tested group, the active medication is the initial medication since, as we shall see 
shortly, the initial medication of the patients affects the modeled observed PRI. For the 
Non-tested group, the active medication is the follow-up medication since it affects the 
patient’s platelet activity level, measured through PRI, afterwards that the physician is 
managing by choosing the medication (the endogenous variable) during follow-up.  
Let 𝑝𝑟𝑖 be a random variable that corresponds to the patient’s PRI under the 
active medication. The distribution of 𝑝𝑟𝑖 captures the physician’s uncertainty about the 
patient’s health outcomes (Figure 3). The physician’s goal is to select a medication 
during the follow-up visit to shift the patient’s 𝑝𝑟𝑖 distribution, their belief of what the 
patient’s platelet activity will be as a result, into the Good health region. In other words, 
we want to understand the physician’s belief about what the patient’s platelet activity will 
be because of her medication choice. In Figure 3, we illustrate the two risks through two 
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potential 𝑝𝑟𝑖 distributions. The distribution in the left of Figure 3 is for a patient with a 
high risk of bleeding; the physician would therefore choose a medication that would shift 
the patient’s 𝑝𝑟𝑖 distribution to the right into the Good health zone (in the center). 
Conversely, a patient with a risk distribution in the right of Figure 3 will have a high risk 
of clotting, and so the physician would choose a medication that would move the risk 
distribution to the left into the Good health zone. 
Figure 3: Patient-Risk Distributions 
 
The PRI could be modeled by any suitable probability distribution 𝑓 𝑝𝑟𝑖;𝒟,𝛩 , 
where 𝒟 is the collection of the patient attributes and 𝛩 is the collection of the 
parameters. While a variety of functional forms are possible, we chose the popular Linear 
Gaussian Model (Roweis and Ghahramani 1999) — a linear function of parameters plus a 
Gaussian error term — due to the ease of interpreting their parameters and its connection 
to the ordered Probit model that is well suited to the choice among available health 
outcomes. We specify the PRI distribution as:  
		
21 
𝑝𝑟𝑖 = 𝛽! + 𝛽! 𝑋 + 𝜇 !𝑀𝑒𝑑! + 𝜇 𝑀𝑒𝑑! + 𝛾! 𝐺 + 𝜂𝑀𝑒𝑑! ∗ 𝑆𝑡𝑒𝑛𝑡 + 𝜁 𝑀𝑒𝑑! ∗  𝐺+ 𝜖 
or  𝑝𝑟𝑖 = 𝛩 ′𝒟 + 𝜖 (1) 
where, 𝛽! is a Tested or Non-tested group-specific intercept.  𝑋 is a vector containing the patient’s demographics, co-morbidities, type of stent, 
and location of stent.  𝑀𝑒𝑑! is the active medication (0: Ticagrelor, 1: Clopidogrel) that affects the 
modeled PRI through the bio-chemical mechanism.  𝑀𝑒𝑑! is the initial anti-clotting medication (0: Ticagrelor, 1: Clopidogrel). This 
variable is included to capture the effect of the physician’s knowledge of the 
patient- and provider-specific factors on the PRI that could lead to the initial 
choice of the medication.  𝐺 is the genotype group dummy variable — a three-element 0/1 vector. The Rapid 
group is used as the baseline. 𝜖 ~ 𝑁𝑜𝑟𝑚𝑎𝑙(0,𝜎) is a random variable, the distribution of which captures the 
physician’s uncertainty about the PRI the patient would eventually achieve. 𝜎 is a 
parameter to be estimated.  𝑆𝑡𝑒𝑛𝑡 is a binary variable containing the patient’s stent type (0: bare metal stent, 
1: drug-eluting stent).  
An interaction term between initial medication and the type of stent is included 
because there could be an association between the two. For example, patients 
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from a higher socioeconomic status are more likely to get both the more 
expensive stent and the more expensive medication.  
An interaction term between genotype and the active medication is included 
because the efficacy of the Clopidogrel depends on the patient’s genotype. 
The Tested and Non-tested patient groups provide us two types of information. 
Since for the Tested group we have the genotype group and the PRI values, it allows us to 
model the PRI as a function of the patient attributes and the initial medication for 
different genotypes. For the Non-tested group, on the other hand, we have the physician’s 
choice of medication based on the underlying PRI model; therefore, the data from the 
Non-tested group allows us to estimate the role of the patient’s socioeconomic-status and 
the physician’s estimate of the disutility of the outcomes on the medication choice in 
addition to the impact of patient’s health attribute on the PRI distribution. The availability 
of different sets of variables requires different types of models for each group: a model of 
PRI in the Tested group and a model of physician’s medication choice in the Non-tested 
group. The overview of the model is given in Figure 4. We describe each component 
next. 
Tested-group PRI model: We estimate the relationship between the PRI and patient 
attributes, including the genotype, shown in Equation (1). The active medication is the 
same as the initial medication because the PRI in the Tested group is measured under the 
initial medication. The Tested group’s specific intercept parameter 𝛽!! is used, which 
leads to the following equation for the Tested group’s PRI: 
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𝑝𝑟𝑖 = 𝛽!! + 𝛽! 𝑋 + 𝜇 ! + 𝜇 𝑀𝑒𝑑! + 𝛾! 𝐺 + 𝜂𝑀𝑒𝑑! ∗ 𝑆𝑡𝑒𝑛𝑡 + 𝜁 𝑀𝑒𝑑! ∗  𝐺 + 𝜖 (2) 
Because 𝜖 in Equation (2) follows the Normal distribution, the likelihood of the 
parameters from the Tested group’s data follows from the Normal distribution probability 
density function:  
𝑓 𝑝𝑟𝑖|𝛩,𝒟,𝜎 = 1𝜎 2𝜋 𝑒!!! !!!!𝒟! ! (3) 
 
Figure 4: Overview of the proposed model 
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Non-tested group decision model: We assume that the provider selects the follow-up 
medication that leads to the lowest expected overall disutility for the patient. The choice 
of medication affects the PRI distribution as shown in Equation (1). However, it is not the 
PRI but the resulting health outcomes — bleeding, good health, or thrombosis — that 
present the disutility consequence for the patient. Additionally, as discussed in the 
introduction, the cost of the treatment can play a role in the decision as well. Thus, the 
expected disutility for a patient in the Non-tested group, including that from the adverse 
health outcome and the price of the medication, is: 𝐸! 𝐶|𝐷,𝑀𝑒𝑑!;𝛩= 𝐶!! ×𝑃 𝑅 𝑋,𝑀𝑒𝑑! ,𝐺,𝑀𝑒𝑑!;𝛩,𝜎 𝑃 𝐺 + 𝜋! 𝑆𝐸𝑆 𝐶!"!! + 𝜀 (4) 
Considering the impact of both health and economic factors in physician’s decisions in 
Equation (4) allows us to understand the tradeoff between the two as well as estimate the 
impact of changes to the economic factors on patient disutility (explored in the policy 
section).  
The first summand on the right-hand side of Equation (4) is the expected disutility 
due to health outcomes. The data vector 𝐷 contains the same set of variables as in 
Equation (1), except 𝑀𝑒𝑑! and 𝐺. The physician does not have access to the genotype 
group in the Non-tested group. Therefore, she must decide on a medication based on the 
expected disutility given the distribution of the genotype groups in the population. 𝑅 is a three-element random vector with only one element that is 1; the other two are 0. 
These values represent the potential health outcomes and are constructed from the 
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random variable 𝑝𝑟𝑖 in the following manner (Brar et al. 2011): 𝑅[1] = 1  iff 𝑝𝑟𝑖 < 0.16 𝑅[2] = 1 iff 0.16 ≤  𝑝𝑟𝑖 < 0.50 𝑅[3] = 1  iff 𝑝𝑟𝑖 ≥ 0.50 
(Bleeding) 
(Good Health) 
(Clotting) 
(5) 
𝑝𝑟𝑖 is modeled as a random variable following the Normal distribution as shown in 
Equation (1), but with two changes from the Tested group model. First, in the case of the 
Non-tested group, the 𝑀𝑒𝑑!, the initial medication, is conceptually separated from 𝑀𝑒𝑑!, 
the medication the physician can choose to switch the patient to during the follow-up 
visit. These are different variables possibly with different values for the Non-tested 
group. Second, we allow different intercepts in the Non-tested and Tested groups to 
capture any potential difference in the two populations that can affect their PRI 
distribution. However, the remaining parameters are the same across both groups. That is, 
as per Rational Expectation assumption, we assume that the physician’s knowledge of the 
relationship between various patient attributes, medication, and PRI is the true underlying 
relationship that governs the PRI distribution in the Tested group. This leads to the 
following equation for the Non-tested group PRI: 
𝑝𝑟𝑖 = 𝛽!! + 𝛽′ 𝑋 + 𝜇 !𝑀𝑒𝑑! + 𝜇 𝑀𝑒𝑑! + 𝛾′ 𝐺 + 𝜂𝑀𝑒𝑑! ∗ 𝑆𝑡𝑒𝑛𝑡 + 𝜁 𝑀𝑒𝑑! ∗  𝐺 +𝜖  (6) 
Where, 𝛽!! is the intercept for the Non-tested group.  
The specification in Equations (5) and (6) is equivalent to the Ordered Probit 
model (Greene, 2003), albeit with a latent outcome variable, 𝑅, as opposed to the 
observed categorical variable modeled in the standard Ordered Probit. The observation 
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we model is the medication that the physician chose based on the probability of these 
latent health outcomes and their expected disutility (to be described shortly). We set the 
disutilities from the patient’s suffering for the three medical outcomes as 𝐶 =  {1, 0, 𝑐!}. 
The Optimal Health disutility is set to zero. The bleeding disutility is set to one. The 
clotting disutility, 𝑐!, is expected, but not assumed to be greater than one; it is estimated 
along with the other parameters in our model. The clotting disutility relative to bleeding 
disutility was difficult to obtain directly from the physicians. Nonetheless, we gathered 
from our discussion with the physicians that it is perceived as a major risk, hence plays a 
significant role in their decisions. The estimated value of 𝑐! could help us understand the 
degree to which the thrombosis disutility is greater than the bleeding disutility in the 
physician’s view. 
The second summand of Equation (4) contains the disutility associated with the 
price of medication. 𝑆𝐸𝑆 is a two-element vector; one element is 1 and the other, 0. The 
first element is 1 if the patient has a low socioeconomic-status (poor). The second 
element is 1 if the patient has a high socioeconomic-status (rich). The  𝜋 = [𝜋!,𝜋!] is a 
parameter vector that captures the patients’ cost-sensitivities from low and high 
socioeconomic-status. Thus 𝜋! 𝑆𝐸𝑆 in Equation (4) is the cost-sensitivity of the patient 
under consideration. For the medication prices, 𝐶!"!!, we assume, without any loss of 
generality, that the price of the less costly medication, Clopidogrel, is zero, and the price 
of more expensive medication, Ticagrelor, is one. Since we are estimating 𝜋, the actual 
medication price is absorbed into the 𝜋s. 
 𝜀 captures any additional factor that affects the physician’s estimate of the 
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disutility, but that we do not observe — an econometric error term. We model 𝜀 as a 
random variable following Type I Extreme Value distribution. 
A physician chooses the follow-up medication, 𝑀𝑒𝑑!, which minimizes the 
patient’s total disutility. This can be modeled using a choice model in which the 
probability of the physician prescribing 𝑀𝑒𝑑!, (i.e., the value observed) for a patient in 
the Non-tested group is given by the following multinomial logit:  
𝑃 𝑀𝑒𝑑!|𝐷,𝛩 = 𝑒!!! !|!,!"!!;!𝑒!!! !|!,!"!!! ;!!"!!!  (7) 
where, 𝑀𝑒𝑑!!  indexes over the two possible medications from which the physician can 
choose: Clopidogrel (0) or Ticagrelor (1).  
The likelihood of the parameters is computed based on the entire dataset, 
including both Non-tested and the Tested groups of patients, using Equations (3) and (7). 
The joint likelihood is: 
1𝜎 2𝜋 𝑒!!! !"#!!!!𝒟!! !!!"#$"%!!!!"#$"% !"#$% !"#$%$&'&() ×
𝑒!!! !|!! ,!"!!,!;!𝑒!!! !|!!,!"!!! ;!!"!!!
!!"#!!"#!"$
!!!!"#!!"#!"$ !!"#$ !"#$%$&'&()
 (8) 
Note that in Equation (8), the parameters 𝛩 and 𝜎 are shared across the models of 
the Tested and Non-tested groups, thus are estimated from the data from both the patient 
groups. Estimation from this joint likelihood allows us to learn how the patient attributes 
and medications affects the PRI distribution from both the observed PRI values in the 
Tested patients and the physician’s choices, based on how PRI is affected by patient 
attributes and medications, in the Non-tested patients. That is, although PRI is not 
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observed in the Non-tested group, the physicians’ choices allows us to infer the likely 
PRI distribution given the attributes, enabling us to learn the PRI model parameters from 
both groups of the data. 
We estimated the parameters by maximizing the likelihood using the limited-
memory BFGS quasi-Newton method implemented in the minFunc software (Schmidt 
2005). The standard errors of the parameters are computed by estimating the information 
matrix from the gradients of the likelihood function at the maximum likelihood estimates 
of the parameters (Wasserman 2004). For ease of reference, we call our proposed model 
the Health and Economic factor based Medication Choice (HEMC) model.  
Validation 
Before we discuss the parameter estimates and the implications of the parameter values, 
we assess how well the HEMC model describes the physician’s medication choices 
compared to other benchmark models. We do this by comparing the error rate of the 
HEMC model with that of three well-known classifiers — the Decision tree, Logistic 
regression, and the Support-vector machine — in predicting the physician’s choices of 
follow-up medication in a subset of data held out from the Non-tested group. The rest of 
the data from the Non-tested group and all the data from the Tested group are used for 
training the models. The physician’s choice of medication is used as a variable to predict 
since our objective is to study whether the Genomic test result influences the physician’s 
medication decision. We restricted our predictions to the Non-tested group because we 
know the actual physician’s decision, only for this group. 
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The predictors for the benchmarks include the health and demographic attributes 
in 𝒟 in Equation (1) and a dummy variable indicating whether the patient received a 
genomic test (since this information is used in the HEMC model). The estimated Logistic 
regression is:  𝑀𝑒𝑑! ~ 𝛽! 𝒟 + 𝜏 𝑇𝑒𝑠𝑡 + 𝜋 𝑆𝐸𝑆 (9) 
Where, 𝑀𝑒𝑑! is the medication recommended at follow-up. For the tested group, it was 
the clinically recommended follow-up medication, obtained from the practice partner, 
based on PRI and genotype group observed from the test. 𝑇𝑒𝑠𝑡 is a binary variable 
indicating whether the patient received a genomic test. 𝑆𝐸𝑆 is a binary variable indicating 
the socioeconomic status of the patient (0: low, 1: high).  
These predictors are also used in the support vector machine and decision tree 
classifiers. For the support vector machine, a Gaussian kernel, was selected because it 
produced the lowest prediction error compared to linear and polynomial kernels, 
estimated using Matlab fitcsvm() routine (Mathworks 2017). 
The held-out subset is rotated in a 10-fold cross-validation to ensure that the 
methods are tested on each record in the Non-tested group. The average prediction 
accuracies over the 10 folds are reported in Table 2. In this table, we also include the 
Zero-R method, that simply predicts the most common value of the dependent variable 
(Witten et al. 2011). The performance of this simple benchmark would help us assess the 
incremental benefit from the more sophisticated approaches. 
We find that the proposed model has a 6% lower error rate than that of the best 
benchmark (23% relative reduction in error). One reason for this improved performance 
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is that, although all the compared models use the same set of variables, the proposed 
model incorporates some of the domain knowledge of how physicians make decisions 
using the structural econometric framework, whereas the benchmarks are general-purpose 
classifiers.  
 
Table 2: Model Error Comparison 
Model Error (%) 
Zero-R 40.5 (2.4) 
Decision Tree 30.9 (2.2) 
Logistic Regression 34.1 (2.3) 
Support Vector Machine with Gaussian Kernel 26.6 (2.1) 
Health and Economic factor based Medication Choice (HEMC) model 20.6 (1.9) 
Note: standard errors are in parenthesis.  
Since, the proposed model captures the physicians’ behavior better than the 
benchmarks, we proceed to examine the parameters of the estimated model to gain 
insight into the physician’s decision-making process and further analyze it to examine the 
economic implications of being able to estimate the patients’ risk profiles through a 
statistical model. 
Results  
In this section, we first examine the parameter estimates to understand the 
physicians’ decision-making process. Then we apply the estimated HEMC model to 
predict the clinical impact of the genomic test for different patient profiles and evaluate 
the predictions on held-out datasets. 
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Parameter Estimates 
The parameter estimates provide several key observations (Table 3). First, the 
magnitudes of the economic coefficients, 𝜋! = 0.474 and 𝜋! = 0.858, measure the 
disutilities imparted by the price of the more expensive medication, Ticagrelor, to the 
high and low socioeconomic-status patients respectively — the cost sensitivities of the 
patients from each status. The relative values of 𝜋s suggest that the more expensive 
medication hurts the patients from the low socioeconomic-status 81% more than it does 
the patients from high socioeconomic-status. While 𝜋! is positive and significant, 𝜋! is 
not significantly different from zero. The magnitude difference and the significance of 𝜋! 
suggest that physicians consider the socioeconomic-status of the patients when assigning 
follow-up medication. 
The second interesting parameter is the physician’s assessment of the disutility of 
clotting, or 𝑐!. Since the parameter is significant, we can conclude that when the 
physician chooses a follow-up medication, she considers the relative costs of the two 
risky outcomes (i.e., bleeding vs. clotting) associated with the two anti-clotting 
medications. Moreover, the relative cost of clotting compared to that of bleeding is 
5.83:1. As we discussed in the results, this estimate is difficult to obtain directly from the 
physician by asking, but the estimates of the 𝑐! parameter indicate that the physician 
chooses the medication as if the cost of clotting was about six times larger than the cost 
of bleeding. 
Several other health condition related parameters are significant, suggesting that 
they impact a patient’s PRI. Therefore, could we use this learned model to assess the risk 
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profile of a new patient and determine if the genomic test results will make a difference 
in their follow-up medication? We seek to answer this question next. 
 
Table 3: Parameter Estimates 
Parameter Estimate Parameter Estimate 
Parameters of the Linear PRI model   
Non-tested group Intercept 0.218 Gene Variants (Rapid group used as baseline) 
Tested group Intercept 0.054 Normal Gene 0.050 
Demographics  Intermediate Gene 0.005 
Age (1: > 60) 0.018 Poor Gene 0.033*** 
Sex (1: Male) 0.020*** Medication Effects  
Health Condition  Active-medication 0.522* 
BMI (1: ≥25) 0.001 Active-medication × Normal Gene -0.194 
Angina 0.058*** Active-medication × Intermediate Gene -0.127*** 
Previous Stent (1: if present) -0.020 Active-medication × Poor Gene -0.269 
Stent Type (1: Drug Eluting) -0.025*** Initial-medication 0.127*** 
Hypertension -0.018*** Initial-medication × Stent Type -0.390*** 
Heart disease 0.014   
Diabetes 0.036***  
Stent Location  Economic parameters in the medication choice model 
Left Arterial -0.015 Cost sensitivity of patients of low SES 0.858*** 
Left Circumflex 0.002 Cost sensitivity of patients of high SES 0.474 
Right Coronary 0.000 Disutility of thrombosis 5.83*** 
Note: p-values are denoted as: *** < 0.01 < ** < 0.05 * < 0.1. 
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Identifying Patients Most Likely to Benefit from the Test 
In this section, we predict, and evaluate, whether the genomic test will make a difference 
in the physician’s choice relative to no genomic test. The overview of the evaluation is 
the following: we match the patients in the Tested and Non-tested groups on a subset of 
attributes to form matched pairs of groups. Using each such matched pair, in turn, as a 
held-out dataset, we measure the change in the observed rate of switching of medication 
for the patients when they are tested relative to similar patients who are not tested. 
Meanwhile, using the HEMC model trained on the rest of the dataset, we predict how 
much the probability of switching medication for the patients in the held-out dataset 
would change if they are given the genomic test. Comparison of the prediction with the 
observed change in the rate of medication switching allows us to measure how accurately 
HEMC can estimate the probability of a decision change because of the genomic test. 
Thus, the evaluation combines the matching method to measure causal treatment effect 
(Stuart 2010) and cross-validation to evaluate the predictive performance of statistical 
models (Arlot and Celisse 2010) to evaluate the performance of various models in 
predicting the causal impact of a genomic test on medication decision. 
What subset of attributes should we use to match the two groups? Exactly 
matching patients in the two groups using all the 13 attributes shown in Table 1 would 
select a small subset of patients from each group — only those who have patients in the 
other group who look virtually identical to them across all 13 attributes. In a large 
dataset, we can exactly match the patients from the two groups and still have adequate 
number of records in the matched groups for statistical power. Unfortunately, in our case, 
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matching on all the attributes led to only 70 records (out of 427), which does not provide 
enough data for a reliable conclusion. Therefore, we relax the criteria to only a subset of 
attributes. Nevertheless, by carefully selecting the attributes, as described shortly, we are 
able to match the patients in the Tested group to those in the Non-tested group who are 
equally likely to get tested. By comparing such matched Non-tested and Tested groups 
we remove any potential selection bias in the Tested group and measure the causal effect 
of genomic testing on medication switching.  
This is similar in spirit to the propensity score matching for causal inference, 
where subjects in the Non-tested and Tested groups with the same probability of being 
treated are matched (Rosenbaum and Rubin 1983). However, one difference is that in 
propensity score matching, the combination of attribute values for both sides of a match 
can differ — only the propensity scores (a function of those attributes, need to match. 
Indeed, this feature enables propensity score matching to match a large number of 
subjects across two groups. This is appropriate when one is interested in the average 
treatment effect in a population. However, such score-based matching would distance our 
evaluation from an application scenario where a practitioner is interested in the 
heterogeneous effect of the genomic test for different attribute combinations (the patient 
profiles). Therefore, we match the patients in the Tested and Non-tested groups not only 
by their propensity of being tested, but also by their attributes that are significant 
determinants of this propensity. This is a stricter criterion for matching, with fewer 
matches, than the propensity score.  
We operationalize this using a logistic regression, commonly used in propensity-
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score matching, to predict whether a patient will get the genomic test based on their 
health and demographic attributes. We find five significant attributes: the initial 
medication, the type of stent, whether they have received a stent previously, if the stent is 
in the left circumflex (the most complicated procedure), and whether heart disease is 
comorbidity. We then matched patients in the Tested and Non-tested groups who had 
identical values in all these five attributes — the patients in these matched pair of groups 
are equally likely to receive the genomic test. After such matching, we found 17 pairs of 
groups in our dataset, containing a total of 265 patients. Measuring the differences in 
switching rates across these matched groups removes the selection bias in testing and 
measures the causal effect of a genomic test on the rate of switching of medication. 
For each patient with attributes 𝐷 within each matched pair of groups, we 
estimate the probability that the physician would switch medication at follow-up, if not 
given the test, 𝑃!"#$%!! , using Equation (7). However, if a patient is given the test, the ex-
ante probability of switching is computed by taking expectation of probability of 
switching over all possible genotype groups (since the genotype group is not observed 
before the test). This leads to the following ex-ante probability of switching if tested:  
𝑃!"!"#!! = 𝑃 𝐺 ×𝑃 𝑀𝑒𝑑! ≠ 𝑀𝑒𝑑! 𝐺;𝛩,𝐷,𝜎!  (10) 
where the probability that the follow-up medication, 𝑀𝑒𝑑!, would take a certain value is: 
𝑃 𝑀𝑒𝑑!|𝐷,𝐺;𝛩,𝜎 = 𝑒!! !|!,!"!!,!;!𝑒!! !|!,!"!!! ,!;!!"!!!  and (11) 𝐸 𝐶|𝐷,𝑀𝑒𝑑! ,𝐺;𝛩 = 𝐶!×𝑃 𝑅 𝐷,𝐺,𝑀𝑒𝑑!;𝛩,𝜎  (12) 
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The Equation (11) follows from Equation (7) when we replace the expectation of 
disutility over all genotype group, 𝐸! 𝐶|𝐷,𝑀𝑒𝑑!;𝛩 , by the expectation conditional on 
the genotype group, 𝐸 𝐶|𝐷,𝑀𝑒𝑑! ,𝐺;𝛩 . The probability of medication choice for the 
Tested group (Equation (11)) depends on the genotype group 𝐺, as we expect the 
physician to consider this when choosing the follow-up medication after the test. 
However, for the Non-tested group (Equation (7)), the probability of the medication 
choice does not depend on 𝐺 (it is marginalized out in the physician’s expected disutility 
calculation), as the physician must make the decision without this information. For each 
matched pair of groups, the change in the estimated average probability of switching 
medications when the patients are tested, computed using Equation (10) and (11), relative 
to when they are not tested, computed using Equation (10) and Equation (7), is our 
predicted change in the probability of switching if a patient in the group is given the 
genomic test. 
We also predict the change in switching probability using the benchmarks tested 
previously. Each of the learned benchmark classifiers is used to compute the probabilities 
of medication switching, with and without the genomic test, for each patient in a matched 
pair of groups. The change in the average estimated probability of switching medication 
in each matched group is used as the benchmark’s predicted change in medication 
switching probability if the patients in the group are given the genomic test. 
Since, the disutility-minimizing physician chooses to switch if and only if the 
disutility decreases from doing so, the probability of switching can be treated as a proxy 
for the expected reduction in disutility. Therefore, a more accurate prediction of the 
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change in the probability of medication switching due to a genomic test indicates a more 
accurate estimation of the benefit a patient with a given profile is expected to get from the 
genomic test. 
Evaluation 
We hold out each pair of matched groups from the data, one pair at a time, and estimate 
the model anew using the remaining data. Using the estimated parameters, we compute 
the change in average probability of switching when given the genomic test (𝛥𝑃!"#$%!) 
for the held-out matched pair of groups. Separately, using the held-out matched pair of 
groups, we measure the difference between the observed probabilities of switching in the 
Tested and the Non-tested groups (𝛥𝑟!"#$%!). We measure the correlation between the 𝛥𝑃!"#$%! and the 𝛥𝑟!"#$%! from all the matched pairs to assess if the 𝛥𝑃!"#$%! is a good 
predictor of the 𝛥𝑟!"#$%!. We use the Spearman’s rank correlation coefficient because the 
goal is to identify those who are likely to benefit the most from the genomic test; the 
exact magnitude of the benefit is less important. Similar correlations are measured for 
each of the three benchmarks for comparison purposes (Table 4). 
Table 4: Correlation Between the Observed Change in the Switching Rate and the 
Predicted Change in the Probability of Switching Using Different Methods 
Prediction method Spearman’s correlation 
Proposed Health and Economic factor based 
Medication Choice (HEMC) model 
0.37 
Logistic regression 0.33 
Support Vector Machine with Gaussian kernel 0.20 
Decision tree 0.27 
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The results show that the predicted changes in medication-switching probabilities 
due to genomic testing are positively correlated with the changes in observed switching 
probabilities when the genomic test is given (with correlation of 0.37). When we compare 
this correlation with the correlation produced by the benchmarks, we find that HEMC 
predicts the changes to the medication switching rates for the patients, when they are 
given the genomic test, more accurately than the benchmarks. As discussed, the more 
accurate estimation of the probability that the data gained from the genomic test would 
make a difference in the physician’s choice of the follow-up medication could be due to 
the HEMC model’s ability to incorporate the domain knowledge of physicians weighing 
different health outcomes and their resultant disutilities. Conversely, the general-purpose 
classifiers used as benchmarks are not designed to incorporate such insight, although they 
use the same set of attributes as HEMC.  
We obtain additional insight into the prediction of medication-switching decisions 
by plotting the observed rate of medication switching against the change in probability of 
switching predicted by HEMC (Figure 5). Note that correct predictions are both in the 
top-right quadrant, groups where the patients are more likely to switch with the genomic 
testing, as well as in the bottom-left quadrant, where the patient is less likely to switch 
after genomic testing than she was before genomic testing. The latter can occur if the 
prescribed medication change, without the genomic test, is a poor choice for the patient 
and is prevented when the patient undergoes the genomic test. 
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Figure 5: Change in Probability of Switching Medication After Testing for each of the 17 
Matched Groups 
 
Note: Each circle represents one matched-pair of groups. The area of the circle is proportional 
to the number of patients in the pair of groups (shown to the right of the circles).  
The average change in the observed rate of switching, 𝛥𝑟!"#$%!, when the patients 
undergo the genomic test across the 17 groups is -0.01 (standard error = 0.06); that is, the 
considerable heterogeneity in the genomic-test effect across patients with different 
profiles, shown in Figure 5, which is identified with HEMC, is masked in the average 
effect. Moreover, simply by comparing the rate of switching in Non-tested vs. Tested 
groups (see Table 1), 15.8% and 28.6% respectively, one might incorrectly conclude that 
more switching occurs due to the genomic test. But, matching the patients by the 
attributes responsible for their assignment to Tested versus Non-tested groups removes 
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this difference, suggesting that the higher switching rate for the Tested group could 
largely be a selection effect. 
Finally, what are the profiles of the patients who are likely to benefit from the 
genomic test? In Figure 6, we plot the average reduction in disutility in each of the 17 
profiles in the decreasing order of their benefit. We see a clear separation between 
patients who are and those who are not expected to benefit from the test. The top 9 
profiles are likely to see the benefit encompass 112 of the 265 patients in our matched 
population. Analyzing the attributes of the two types of profiles reveals that the patients 
who have Drug Eluting Stents, and generally those who have had a prior stent surgery or 
those who have a more complex procedure (stent at the left circumflex) are expected to 
derive the most benefit from the genomic test. Those who have a bare metal stent, or 
undergoing a stent surgery for the first time, or undergoing a simpler procedure, are 
expected to derive very little benefit from the test. 
Figure 6: The average disutility reduction in the 17 patient profiles.  
 
0 0.1 0.2 0.3 0.4
Ticagrelor, Healthy, Complex, Prior Stent, Drug Eluting
Ticagrelor, Healthy, Simple, First Time, Bare Metal
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Policy Analysis 
Using the estimated HEMC model, we study the welfare implications of three 
policy interventions. The first intervention prioritizes genomic testing for patients who 
would benefit the most. The second explores the impact of such prioritization on the pace 
of adoption of the new genomic test as the price of the test decreases over time. The third 
explores a revenue-neutral subsidy policy to minimize the total disutility of the 
population utilizing the estimates of the patients’ cost-sensitivities and each patient’s 
unique expected disutility reduction. 
Welfare Implication of Prioritized Testing 
In this set of policy simulations, we evaluate two different testing strategies (random 
selection vs. selection guided by the model) for genomic testing under two prices (zero 
cost of testing vs. the current cost of the genomic test). We start by calculating the 
reduction in expected ex-ante disutility for every patient when she receives a genomic 
test versus when she does not as: 𝛥𝐶
= min!"!!! 𝐶!! ×𝑃 𝑅 𝐷,𝐺,𝑀𝑒𝑑!!;𝛩,𝜎 𝑃 𝐺 + 𝜋! 𝑆𝐸𝑆 𝐶!"!!!!"#!!"#$ !"#$%"&"%' !!!" !"# !"#!"$− min!"!!! 𝐶!×𝑃 𝑅 𝐷,𝐺,𝑀𝑒𝑑!! ;𝛩,𝜎 + 𝜋! 𝑆𝐸𝑆 𝐶!"!!! 𝑃 𝐺! !"#!$%!& !"#$%"&"%' !!!" !"#!"$  
 
 
From Eq. (4) 
 
From Eq. (12) 
(13) 
Note that the expected disutility estimate considers disutility from the 
probabilistic health outcome and the disutility of the follow-up anti-clotting medication 
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based on the patient’s socioeconomic-status. Minimization occurs in each disutility 
expression in Equation (13) because we consider that the physician would choose 
medication to minimize the total disutility with or without the information from the test. 
Different medication variables (𝑀𝑒𝑑!! and 𝑀𝑒𝑑!! ) are used under the two scenarios to 
make explicit that different medications could minimize expected disutility when the 
patient is not tested vs. tested. 
In the absence of the genomic test cost, the expected disutility reduction is non-
negative. Therefore, the total expected disutility of the population decreases 
monotonically when more patients are tested. In the absence of a model to guide patient 
selection for genomic testing, one might randomly select a subset of patients. We first 
plot the total expected population disutility of this random selection strategy (Figure 7). 
We find that the total disutility of the population decreases, approximately linearly, from 
375 when no patient is tested, to 325 when all 427 patients are tested. In contrast, when 
we select the patients in decreasing order of their expected disutility reduction from 
testing, that is, 𝛥𝐶 from Equation (13), we observe a much quicker reduction in disutility. 
As Figure 7 illustrates, this leads to the minimum total patient disutility of 325 after 
testing only 241 patients. Based on the model, the remaining 186 patients are expected to 
receive no benefit from the genomic testing.  
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Figure 7: Ordered versus Random Patient Testing Policy Simulation 
 
The above policy simulation sets the price of the test to zero to isolate the impact 
of only prioritizing the patients for testing, guided by the model, on the total disutility. In 
the second set of policy simulations, we additionally consider the price of the test. We 
use the current price of the test, which is, 6500 INR or US$ 100 (ℙ!) (Sharma 2013). Let 𝜋! be the disutility incurred by the patient 𝑖 from the difference in price of Ticagrelor 
from Clopidogrel — 36,500 INR or US$ 564 (ℙ!"!!), for the recommended period of 
one year (IndiaMart 2017). Therefore, the disutilities due to unit price is !!ℙ!"!!, which 
leads to: 
Disutility due to price of the genomic test for patient 𝑖 = 𝜋! ℙ!ℙ!"!! (14) 
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= 0.178) multiplied with 𝜋! (= 0.858) for the patients from low socioeconomic-status and 𝜋! (= 0.474) for the patients from high socioeconomic-status. We compute the expected 
disutility reductions by additionally considering the certain disutility that the price of the 
genomic test will generate if a patient takes the genomic test. We then include these 
patients, one at a time, into the group that is tested in decreasing order of this revised 
reduction in the expected disutility and compute the total expected population disutility 
(plotted in Figure 8). For comparison, we also plot the disutility reduction when the 
patients are included in the random order.  
Figure 8: Reduction of the Total Population Disutility under Different Ordering 
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expected disutility increases when the disutility from the test price is included. Therefore, 
a disutility-minimizing physician would not choose the genomic test for these patients 
knowing their expected benefit estimates. In contrast, in the absence of the model, when 
additional patients are randomly selected for testing, the lowest disutility would be 
achieved only after testing everyone in the population. Moreover, the lowest total 
disutility achievable without a model is 368, or 8.3% higher than the minimum of 340 
achievable with the help of the HEMC model.  
These results suggest that by estimating and using the proposed HEMC model, we 
can prioritize patient testing based on the expected patient benefits. This would lead to a 
lower total disutility for the population than would be achievable without a model.  
Adoption of the Genomic Test at Different Prices 
Many new technologies become more affordable over time. When the MyPLATELET 
genomic test is new and expensive, those who are likely to benefit the most, and those for 
whom the financial cost of the test creates the least disutility, are likely to adopt the test 
first — if they can estimate the value based on their unique medical and economic 
circumstances.  
The following result regarding the adoption decision of a patient will be useful in 
analyzing the adoption of the test in the population. Let the cost-sensitivity of the user 𝑖 is 𝜋!, the expected ex-ante disutility reduction for the user 𝑖 if she takes the genomic test is 𝛥𝐶!, and the price of the test is ℙ! then the following statement is true: 
Proposition 1: A utility maximizing cost-sensitive patient will choose to take the 
genomic test if and only if 
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ℙ! < 𝛥𝐶!×ℙ!"!!𝜋!  (15) 
Proof: Since the patient is utility maximizing she would choose to take the test if the 
disutility from the price of the test is less than the reduction in disutility due to the 
information from the test. Therefore, using Equation (14) for the disutility from the price 
of the genomic test, the patient would choose genomic testing if:  
𝜋! ℙ!ℙ!"!! < 𝛥𝐶! ,  
or, since ℙ!"!!and 𝜋! > 0,ℙ! < 𝛥𝐶!×ℙ!"!!𝜋!   
On the other hand, if ℙ! > !!!×ℙ!"!!!! , then 𝜋! ℙ!ℙ!"!! > 𝛥𝐶!. The left-hand side is the 
disutility from the price of test per Equation (14). Therefore, the utility maximizing 
patient would choose to not take the test and instead incur the lower expected disutility 
from health outcome 𝛥𝐶!. ∎ 
Therefore, if each patient in the population has access to her unique expected 
benefit from the test it would be rational to start testing as soon as the price of the test 
falls below max! !!!×ℙ!"!!!! . This is the maximum expected reduction in disutility for 
any patient in the population. However, without access to such estimates, a medical 
provider must rely on the average benefit received by a patient in the population, 𝛥𝐶, and 
decide whether the financial cost of the test for a patient is worth the expected benefits.  
Corollary 1:  There exist two thresholds of test prices below which it would be rational 
to test subsets of the population from each socioeconomic status: (i) only the patients 
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from high socioeconomic status when the price of the test falls below 
!"×ℙ!"!!!!  and (ii) 
all the patients when the price of the test falls below 
!"×ℙ!"!!!! .  
Proof: Replacing the 𝛥𝐶! with the ex-ante disutility reduction without the model, 𝛥𝐶, and 
the 𝜋! with 𝜋! and 𝜋! for the high- and low-socioeconomic status patients respectively in 
Equation (15) we obtain two price thresholds, 
!"×ℙ!"!!!!  and !"×ℙ!"!!!! , for everyone in 
each of the two socioeconomic statuses. Since 𝜋! < 𝜋! and 𝛥𝐶,ℙ!"!! ≥ 0; !"×ℙ!"!!!! ≥!"×ℙ!"!!!! . Therefore, it would be rational to test only the patients from high 
socioeconomic status when the price of the test falls below 
!"×ℙ!"!!!!  and all the patients 
when it falls below 
!"×ℙ!"!!!! . ∎ 
The existence of these thresholds could delay the adoption of the new genomic 
test in the overall patient population. To illustrate the adoption dynamics, in the presence 
of these thresholds as the price of the test decreases over time, we carried out a policy 
simulation where patients in our dataset are tested if they are expected to benefit from the 
test. In Figure 9, we plot the percentages of the population that would be tested and the 
total population disutility — with and without personalized benefit estimates using the 
model — at prices of the test from 25,000 INR to 0.		  
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Figure 9: Adoption of the Test as the Price Falls with and without the HEMC Model 
 
In the patient population in our dataset, the three price thresholds are: max! !!!×ℙ!"!!!! = 24,888 INR (US$ 384), !"×ℙ!"!!!! = 9,012 INR (US$ 139), and !"×ℙ!"!!!! = 4,978 INR (US$ 77). When the test price is higher than 24,888 INR (US$ 
384), none of the patients in our dataset would expect to reduce their net disutility by 
taking the genomic test. Therefore, even with access to a model that can estimate the 
value that each patient is expected to gain, no one would take the test. As the test price 
declines, patients who would benefit the most would start taking the test. As a result, the 
total disutility would reduce due to testing even with a relatively high price. The total 
disutility declines steadily until the test price reaches 0, at which point it is beneficial for 
the entire population to undergo the genomic test. 
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On the other hand, without access to a statistical model, the net expected benefit 
from the test is not positive for anyone in the population until the price of the test falls 
below 9,012 INR (US $139) — keeping the total population disutility at the highest level 
of 375 until this price point. As the price of the test falls below 9,012 INR (US$ 139), all 
the patients in the high socioeconomic-status would opt in for the test. The participation 
level would remain the same until the price falls below the second threshold of 4,978 INR 
(US$ 77). Nevertheless, the disutility of the patients from the high socioeconomic-status 
would continue to decrease with decreasing test price. When the test price falls below 
4,978 INR (US$ 77), it would be ex-ante optimal for each patient in the dataset to take 
the test. 
These results illustrate the possibility that with the help of the proposed HEMC 
model, patients could take advantage of the genomic test much earlier; those who stand to 
benefit the most would adopt first. At every test price, the total disutility of the 
population would be lower when the learned model is used to select patients for genomic 
testing. Although, HEMC enables earlier adoption, it does not always select more 
patients for testing. For example, when the price falls below 9,012 INR (US$ 139), 
approximately 75% of the population will be tested without a model compared to only 
33% when they are selected using the HEMC model. 63% of these additional patients 
who are tested without HEMC would see an increase in their disutility ex-post, after 
factoring in the financial-cost of the test: although their average net disutility would drop, 
it would not decrease for everyone given their unique attributes. Such uniqueness cannot 
be leveraged without a model of the disutility. Similarly, when the test price falls below 
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4,978 INR (US$ 77), based on the average benefit of the test, the ex-ante expected benefit 
would be positive for everyone. However, if everyone were tested, at the price point just 
below 4,978 INR (US$ 77), 67% of the patient population would incur higher disutility 
after considering test’s financial cost. In fact, when patients are selected using HEMC, 
49% of the population will not be tested until the price of the test reaches zero. Not 
testing those 49% who are not expected to derive any benefit from the test would be the 
total disutility minimizing strategy. 
Revenue-Neutral Subsidy for the Low Socioeconomic-status Patients 
From the parameter estimates we find that the patients of low socioeconomic status incur 
approximately 81% higher disutility from the financial cost of the treatment (Table 3). 
Therefore, some of these patients might forego the opportunity to reduce the disutility 
from adverse health outcomes because of the financial cost of the test. In this policy 
simulation, we explore if we can provide a subsidy to the low socioeconomic-status 
patients while raising prices of the test to make it revenue neutral for the test provider, 
such that the total disutility of the population is lowered. Due to the price discrimination, 
the total disutility achieved in this manner could be even lower than that achieved 
through prioritized testing alone using uniform test pricing. Revenue neutrality is 
important for such a pricing strategy to be adopted by the genomic test provider. As the 
test prices are altered for the high and low socioeconomic status patients, the expected 
demand from each group will change. The revenue-neutral pricing strategy needs to 
compute the required subsidy and markup considering the new demands from both 
groups. 
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The revenue-neutral subsidy for total disutility minimization is given by the 
solution to the following problem (the RNS calculation problem): max!! 𝐶! 𝛥! + 𝐶! 𝛥! Disutility-reduction Maximization
such that 𝑛!! 𝛥! 𝛥! + 𝑛!! 𝛥! 𝛥! = 𝑛! + 𝑛! Revenue-neutrality Condition  (16) 
where, 𝛥! is the multiplication factor, expected to be < 1, to obtain the new subsidized 
price from the current price for the patients with lower socioeconomic-status; 𝛥! is the multiplication factor, expected to be > 1, to obtain the higher price of the test for 
the patients who are not of low socioeconomic-status; 𝑛!! 𝛥!  and 𝑛!! 𝛥!  are the demands from patients with low and high socioeconomic-
statuses, respectively, at the new test prices; 𝑛! and 𝑛! are the number of patients from the low and high socioeconomic-statuses, 
respectively, who are expected to be tested at the current price; 𝐶! 𝛥!  and 𝐶! 𝛥!  are the total expected disutilities of the patients from the low and 
high socioeconomic-statuses after those who are expected to benefit from the test at the 
new prices are tested. 
A polynomial time algorithm to solve this problem is given in the Appendix I. We 
solve the RNS calculation problem to obtain the optimum subsidy for those in the low 
socioeconomic-status, the corresponding markup for the rest, the subsets of patients from 
both socioeconomic-statuses who would adopt the test, and the resultant total population 
disutility (Table 5). 
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Table 5: Adoption and Disutilities at the Optimum Revenue-neutral Subsidy 
 
Low socioeconomic status 
(N=107) 
High socioeconomic status 
(N=320) 
Total 
disutility 
 
Price 
Factor 
Number of 
patients tested 
Price 
Factor 
Number of 
patients tested 
 
Original price 1 16 1 86 340 
Subsidized 0 25 1.186 86 338 
 
We find that when equipped with the expected disutility-reduction information 
from HEMC, at the current price, only about 15% (16 out of 107) of the patients from the 
low socioeconomic-status and 27% (86 out of 320) of the patients from the high 
socioeconomic-status are expected to take the test. This leads to a total disutility of 340 
for the entire population of 427 patients in our dataset or an average disutility of 0.7965. 
However, by solving the RNS calculation problem we find that we can further lower the 
total disutility by subsidizing the test price to zero for the patients from the low 
socioeconomic-status, while increasing the price for the rest by a factor of 1.186 to 
maintain a revenue-neutral pricing policy. In our dataset patient sample, the lower price 
leads to genomic testing of 9 additional patients from the lower socioeconomic-status. 
But, the number of patients from the high socioeconomic-status remains unchanged. 
Overall, this optimal pricing policy would enable healthcare providers to lower the 
average disutility by 0.6% to 0.7916 (338/427) from the earlier average of 0.7965. The 
total disutility of the population as patients are selected in decreasing order of net 
reduction in disutility is plotted in Figure 8. This plot shows that by using the optimum 
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subsidy, the disutility is always lower than the disutility under the original uniform 
pricing. 
Conclusion 
We develop a statistical model of physicians’ choice of medication built on the 
structural econometric framework to understand the value of genomic test information for 
a patient with given attributes. We estimate the model from a dataset collected on 427 
patients in India who have undergone cardiac stent surgery. Using out-of-sample 
predictions on matched pairs of groups of patients, one arm of which receives a genomic 
test and the other does not, we show that the proposed model can more accurately 
estimate the value of the test for a patient than many popular classifiers. Counterfactual 
analyses show that prioritizing patients to test based on their expected benefits could 
lower patient disutility. Further, this could occur sooner in the adoption lifecycle of the 
test than would be achievable without the model. Finally, using the estimated benefits 
and the price sensitivities of each patient, we formulate a revenue-neutral subsidy 
calculation problem that could further lower the total disutility of the patient population. 
This research contributes a predictive model based mechanism to incorporate 
genomic tests into healthcare providers’ treatment process. From a data-driven, process-
design standpoint, our work creates a decision model for prioritizing patients for genomic 
testing based on the value they are expected to derive from it. Our statistical model 
enables healthcare providers to make ex-ante testing decisions based on the predicted 
value of genomic information for each patient to minimize total expected population 
disutility and improve overall population health. 
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This research contributes to recent research in developing predictive models for 
the medical and operational decisions, namely, Bardhan et al. (2015), Somanchi et al. 
(2015), and Lin et al. (2017), by offering an approach to learn such models from the 
decisions of the experts in the domain — the practicing physicians. By using a structural 
econometric framework, we can incorporate the domain understanding into the model of 
the physicians’ decisions. A highlight of our proposed model is the interpretation of the 
physicians’ decisions as choice between potential distributions of a key variable of 
interest (PRI), with each distribution leading to a different patient disutility driven by 
health outcomes and economic cost of the treatment. Such a modeling strategy can be 
used in other healthcare settings where we wish to understand the decision-making 
process of a physician or a patient and the outcomes of their decisions are uncertain, yet 
costly. Such models learned from observation of decisions and contextual variables that 
can affect the decisions could be used to develop data-driven processes in other 
healthcare settings. 
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CHAPTER THREE: PREDICTION OF PATIENT ACTIVATION DURING A 
TECHNOLOGY ENABLED CONTINUITY OF CARE INTERVENTION 
Introduction 
 Chronic disease patients incur 86% of U.S. healthcare costs (Gerteis et al. 2014). 
Effective management of chronic diseases requires both appropriate clinical care and 
patient involvement, including (but not limited to) proper diet, exercise, compliance with 
treatment protocols, and tracking and managing symptoms (Bodenheimer et al. 2002; 
Wagner et al. 1996). Patients’ engagement with their own care is deemed so important 
that it has been labeled the “blockbuster drug of the century” (Chase 2012). Patient 
engagement has been studied broadly to either encompass health outcomes or to examine 
how healthcare systems are designed and governed (Carman et al. 2013, Hibbard and 
Greene 2013). Within the sphere of engagement research, patient activation describes a 
patient’s abilities and inclination to manage their care (Hibbard et al. 2005).  
 Patients with high activation levels make better health related decisions and have 
better health outcomes than patients with low activation levels; this positive association 
holds across a wide variety of patient diagnoses and ethnicities (Alegria et al. 2009; Aung 
et al. 2015; Greene et al. 2015; Hendriks & Rademakers 2014; Marshall et al. 2013; 
Shively et al. 2013). This research stream builds on a validated and reliable questionnaire 
instrument grounded in behavioral science which measures patient activation levels: the 
patient activation measure (PAM, see Hibbard et al. 2005 for validation details). This 
instrument scores individuals (on a theoretical 0 – 100 scale) and classifies them into one 
of four levels: 1) May not believe that the patient role is important in treatment outcomes, 
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“My doctor is in charge” attitude; 2) Lacks confidence and knowledge to take action, “I 
could be doing more” attitude; 3) Is starting to take action, “I’m part of my healthcare 
team” attitude; 4) Has made many behavior changes, but may struggle to maintain 
changes under stress; “I’m my own best advocate” attitude.  
 In addition to the important link between higher PAM levels and better health 
related decisions, knowing PAM levels is important because this allows health care 
providers to improve their responsiveness to the patient, and overall continuity of care 
(Dixon et al. 2009; Rathert et al. 2012; Shively et al. 2013). Continuity of care - defined 
as the degree to which patient experiences individualized care over time, that is “coherent 
and connected and consistent with the patient’s medical needs and personal context” 
(Haggerty et al. 2003 page 1221) – is a key element in supporting patients with chronic 
disease (Holman & Lorig 2004; Wagner et al. 2001). Such care positively influences 
patients’ PAM scores (Turner et al. 2015; Wolever & Dreusicke 2016). Of particular 
interest within this stream of work is the Technology Enabled Continuity of Care 
(TECC), and healthcare providers’ ability to learn (Tucker & Edmondson 2003) wherein 
providers remotely, coherently and consistently provide individualized care and improve 
patient’s health outcomes.  To our knowledge, only one other study uses a remote 
continuity of care solution to assess PAM – this study used telemonitoring and periodic 
telephone calls to assess PAM and healthcare outcomes in diabetic patients (Shane-
McWhorter et al. 2015).  However, that study does not address the issue of whether a 
TECC team can predict PAM, based on patient characteristics. 
 We address this gap by showing how, based on a double loop learning theory 
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(Argyris & Schon 1974), healthcare providers can predict patient activation, and thus 
better provide patient care. Double loop learning has two key mechanisms: the primary 
and secondary loops. In our context, the primary loop (also referred as a single loop) 
refers to a healthcare provider’s increased understanding, and subsequent corrections in 
diagnostic errors, due to patient feedback signals.  The secondary loop, also known as 
double loop, builds into the primary loop patients’ ability to update their mental model 
through two-way feedback with healthcare providers, who then use that feedback to 
refine their guidance, which we term as signals, to their patients. Through these learning 
loops, healthcare providers can better support their patients. Second, and consistent with 
the double loop learning literature (Argyris & Schon 1974), we endow this double loop 
learning framework with the behaviorally grounded concept of system neglect, which 
explains that predictions are often biased with an overemphasis on signals and an under 
emphasis on the environment that produced the signals (Kremer et al. 2011; Massey & 
Wu 2005).  Within this framework, we seek to examine a related set of questions: (1) 
does use of TECC lead to higher likelihood of increased patient activation? (2) Does the 
level of patient activation mediate the relation between TECC and a health outcome?  (3) 
Is it possible to predict which patients are likely to have higher levels of patient 
activation based on (a) the strength of the signal these patients receive from their 
healthcare providers, and (b) the patient’s characteristics?  And (4) if so, are these 
predictions subject to systematic behavioral biases? 
   In order to study these questions, we have designed a field study of TECC 
implementations with congestive heart failure (CHF) and chronic obstructive pulmonary 
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disease (COPD) patients from nine hospitals. We have collected the patients’ PAM 
scores and hospital readmissions data. We examine these data in two related sets of 
analysis. The first analysis investigates the relationship between TECC, PAM and 
hospital readmissions using regression analysis. The second analysis, a prediction model 
using machine learning, frames the measurement and prediction of PAM in a healthcare 
environment. In this way, our theory formulation, data collection and analysis make two 
contributions to the field of patient activation, and allied need for the development of 
predictive analytics methods. 
 I.  We test our learning framework and find support for the association between 
TECC intervention and an increased patient activation levels and a moderated mediation 
effect that leads to reduced readmissions.  
 II. We use this learning framework to demonstrate that a support vector machine 
(i.e., machine learning) methodology can be used to predict patient activation levels. 
Consistent with our posited theory, this prediction is a function of strength of the 
information signal provided by the healthcare providers. We then show these predictions 
reveal under/over estimation biases in patient willingness to change owing to system 
neglect.   
 We close the paper by discussing the implication for our findings in terms of 
predicting PAM, accounting for biases in order to improve TECC implementation, and 
future theory development and design of field studies that ought to focus on unpacking of 
on willingness to change constructs.    
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Hypotheses Development 
 Patients with chronic disease must continuously manage their condition (Tsai et 
al. 2005; Wagner et al. 2001).  For example, patients with congestive heart failure can 
best manage their condition through self-care actions such as consistently taking their 
prescribed medications, following a low salt diet, reaching a healthy weight and 
exercising regularly (Artinian et al. 2002; Cameron et al. 2009).  Although these tasks 
may seem to be straightforward, choosing these actions consistently is notoriously 
difficult (Dickson et al. 2013; Wolever & Dreusicke 2016).  Consistent and repeated 
actions not only allow the patients to better understand their needs, but also to enable 
healthcare providers to learn and adapt to the patient’s unique circumstances. 
 In terms of patient actions, extant work shows personalized feedback to patients, 
such as is provided in continuity of care, provides support for patients to gradually gain 
the necessary skills, resolve, and confidence to incorporate changes (Parry et al. 2006; 
Wolever & Dreusicke 2016) and is an important element of supporting patients with 
chronic disease (Holman & Lorig 2004; Wagner et al. 2001).  In other words, continuity 
of care enables healthcare providers to consistently and repeatedly not only interact with 
patients, but also to learn from patients’ decisions and outcomes in order to update and 
refine support to patients.  In this study, we posit that this continuity of care can be 
provided remotely, using TECC. For this to be effective, the healthcare provision system 
must learn about and adapt to patients. 
 Consistent with Argyris (1976, pp. 365), we define learning as “the detection and 
correction of errors”. Argyris further explains this mechanism by saying: “The detection 
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and correction of error produces learning and the lack of either or both inhibits learning.” 
This lays the groundwork for a single learning loop, which has been described as decision 
makers changing behaviors based on an observed outcome differing from an expected 
outcome (error detection), leading to a change in action believed to better meet the 
expected, or desired outcome (error correction) (Argyris and Schon 1974).   
 Prior studies identify single loop learning as the primal mechanism for explaining 
how healthcare providers make and learn from decisions (Davies et al. 2000; Rudolph et 
al. 2009; Tucker & Edmondson 2003).  Building on this theory base, we combine single 
loop learning with a closely allied concept, signal detection theory, to explain learning in 
the context of a healthcare provider’s actions, while supporting patients with chronic 
disease. Signal detection theory, in the context of single loop learning, posits that 
individual decisions depend on the strength of a signal(s) and individual characteristics 
regarding the interpretation of that signal(s) (Stanislaw & Todorov 1999; Swets 1964). 
From signal detection theory, as a signal gets stronger (less overlap between the signal 
and background noise), it becomes easier to make a correct decision.   
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Figure 10: Single Loop Learning Framework 
 
 Figure 10 illustrates single loop learning, the basis for our theory on healthcare 
providers’ primary actions: error correction to adapt and improve diagnosis.  The 
healthcare provision system, which includes doctors, nurses, family and friends, and 
other information sources, supplies signals - healthcare information and 
recommendations which patients consider when making self-care decisions (Carman et 
al. 2013; Coulter et al. 2008).  These signals may include diet suggestions, medication 
scheduling, and methods to reduce stress and lower blood pressure. However, these 
signals do not provide perfect information. For example, information the patient read on 
the Internet could conflict with information provided by a nurse.  This information can be 
very general (a standardized pamphlet on COPD care), considered a low signal strength, 
or personalized feedback to a patient, accounting for the patient’s circumstances and 
history, considered a high strength signal.  
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 Once a patient receives this information, the patient then makes self-care 
decisions, such as food choices and whether or not to take medication as prescribed.  
After a patient makes a self-care decision, that patient then perceives (accurately or not) 
the result of the decision(s). Although the thousands of decisions a patient makes over 
weeks may vary slightly, a patient’s level of activation – their level of knowledge and 
motivation around their care – informs his/her decisions.  Because we cannot see the 
thousands of micro-decisions made over time (e.g. breakfast and exercise choices for a 
certain day) by patients, we instead measure their aggregate patient activation level that 
has been shown to be highly correlated with patient care decisions and health outcomes 
(Alegria et al. 2009; Aung et al. 2015; Greene et al. 2015; Hendriks & Rademakers 2014; 
Marshall et al. 2013; Shively et al. 2013). Therefore, our model incorporates two latent 
(i.e. observed but not measured) variables – patient self-care decisions and patient 
perceptions of outcome – that influence the patient activation measure. Such aggregation 
of decisions over time is customary practice for learning loops representing continuous 
decision variables (see for instance, an analysis of transactional memory systems, 
Anderson & Lewis 2014) 
 Patients provide aggregate feedback into the healthcare provision system that 
allows healthcare providers to learn from and about the patients, and refine their 
recommendations or support to an individual patient. This feedback from patient to 
healthcare provider and back can occur through face-to-face appointments or digital 
communications (Hu et al. 2018). Regardless of mode, this feedback enables healthcare 
providers to improve support to specific individuals (Street et al. 2009) and focus on 
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challenges specific to a patient. These healthcare provision system inputs function as an 
error correction term. In our system, we propose that if a patient shares observed 
outcomes that are undesirable with the healthcare provision system, that system will 
provide advice to “correct the error” in single loop learning speak.  More specifically, 
patients using TECC will provide daily updates to the healthcare provision system and 
receive frequent feedback from that system (See Appendix 2 for more details.) We 
propose this frequent feedback provides a higher signal strength, enabling better error 
correction, leading to patients with higher patient activation.  Conversely, patients 
without TECC receive significantly less frequent feedback. To be clear, patients without 
TECC are encouraged to see their primary care physician (standard care after discharge 
from the hospital), but do not have daily interaction with the healthcare provision system. 
Thus, patients without TECC receive a lower signal strength, leading to lower PAM 
levels.  Thus, we posit as our first hypothesis:  
 H1: A rise in the level of TECC increases patient activation through error 
correction by care providers. 
 Healthcare providers are interested in raising patient activation because it is a 
proximal variable to measure overall health and healthcare costs (Greene et al. 2015; 
Greene & Hibbard, 2012). Thus, we want to examine the relationship between TECC, 
patient activation, and one longer-term measure of health: hospital readmissions. More 
specifically, we posit that PAM mediates the relationship between TECC and 
readmissions (Figure 11, Panel A).  
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Figure 11: Mediation and Moderated Mediation Models 
 
 Even in the absence of TECC, patients with higher activation demonstrate better 
self-care than those with low activation (Begum et al. 2011; Fowles et al. 2009; Graffigna 
et al. 2017; Greene & Hibbard 2012; Harvey et al. 2012; Hibbard et al. 2015; Zimbudzi et 
al. 2017).  This better self-care leads to better health (Greene & Hibbard 2012; Greene et 
al. 2015), and fewer hospital admissions (Begum et al. 2011; Hibbard et al. 2009; 
Mitchell et al. 2014).  We posit our TECC intervention increases patient activation, which 
improves patient self-care, and health, which in turn reduces readmissions - a patient 
admitted to a hospital within 30 days of discharge from a hospital.  Therefore, we 
propose patient activation mediates a relationship between TECC intervention and 
reduced readmissions:     
 H2a: PAM mediates the relationship between TECC and readmissions.  
 While increased patient activation is a desirable goal, the previous hypothesis 
assumes equivalence across all patients.  That is, if we had two persons with identical 
physiological conditions and one had a higher activation and one had a lower activation, 
the one with the lower activation would have the higher expectation of readmission. 
However, patients do not have identical physiological conditions and physical condition 
can influence activation. Thus, the relationship between TECC, PAM, and readmissions 
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may not be as straightforward as a simple mediation. Research on COPD and CHF 
patients shows that those with more serious and/or immediate health problems are more 
likely to be more actively involved in their self-care (Artinian et al. 2002; Bos-Touwen et 
al. 2015; Cameron et al. 2009; Riegel et al. 2007).  The reasoning is less sick patients are 
not imminently facing severe consequences; self-care changes, such as changing diet and 
making time and effort for exercise are difficult and often prompted by immediate needs 
(Bentley et al. 2005; Dickson & Riegel 2009).   
 Thus, if we have patients with similar motivation levels, as measured by PAM, 
the patients with TECC may be better equipped through the coaching advantage that 
TECC supplies (Gawande 2011; Olsen & Nesbitt 2010; Parry et al. 2006). Thus, the 
effect of PAM on readmissions is not simple; it is also conditional on whether or not the 
patient has TECC, modeled as a moderating factor.  This is referred to as a moderated 
mediation model (Hayes 2013) and illustrated in Panel B of Figure 11. We test this via 
the next hypothesis: 
 H2b: The mediation effect of PAM and readmission, together with the interaction 
effect between PAM and TECC, leads to a lower probability of readmission for a fixed 
value of PAM when TECC is introduced. 
 Not only are higher PAM levels associated with better medium and long-term 
outcomes for patients, but also patients fare better when healthcare providers deliver care 
tailored to their PAM level (Dixon et al. 2009; Rathert et al. 2012; Shively et al. 2013). 
Therefore, it is important to predict PAM for different patients. From H1, we have 
already developed the reasoning for TECC predicting PAM.  In the interest of avoiding 
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duplicate arguments, we thus propose our next hypothesis as a corollary to H1:  
 H3: The prediction of patient activation is positively associated with the use of 
TECC.  
 Given the posited role of patient action in lowering readmissions and other 
undesirable health outcomes, we extend our theory further to predict factors that 
influence such activation. The single loop-learning model presented earlier provides the 
foundational element for predicting PAM, i.e., TECC.  Moreover, this learning requires 
not just valid information from the healthcare provider in the form of TECC, but also 
“receptivity to corrective feedback of the decision-making unit – that is, individual, 
group, or organization” (Argyris 1976 page 365).  A single loop model includes 
information fed back to patients (operationalized as TECC), but does not account for 
patients’ willingness to change.  This matters because single loop learning occurs when 
healthcare providers engage in error correction, but not based upon a patients’ changed 
mental model of how things work. On the other hand, double loop learning takes place 
when actors (in this case, patients) must consider their goals or strategies and possibly 
change these – i.e. change their mental model - which would lead to a change in behavior 
(Argyris & Schon 1974).  In other words, double loop learning requires more reflective 
thought on part of the patients in addition to healthcare provider actions in single loop 
learning, which requires reflexive actions. Prior research investigating healthcare 
decision-making has incorporated double loop learning within decision-making (e.g. 
Davies et al. 2000; Tucker & Edmondson 2003). While these examples examine how 
mental models change to improve obstetrics processes and nurses’ work flow, we believe 
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our context of learning how to more effectively provide support for chronic care patients 
is a new setting. This leads to an enhanced learning framework as shown in Figure 12. 
Figure 12: Double Loop Learning Framework 
 
 Prediction of the patient’s activation level requires the assessment of signal 
strength, and contextual considerations. However, research has shown the persistence of 
biases associated with the processing of the signals - predictors give more weight to a 
signal itself (in our example, the use of TECC) than to the contextual constructs that 
affect the signal (Massey & Wu 2005; Kremer et al. 2011; Mukherjee & Sinha 2017). We 
posit similar outcomes when predicting patient activation. Based on previous findings, 
we contend that patients can increase (or decrease) their activation levels (Chubak et al. 
2012) based on the information signal strength; however patients’ contextual and 
behavioral factors can affect patients’ proclivity to incorporate change into their lifestyle 
and to change their level of activation (Carman et al. 2013).  
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 A patient’s willingness to change forms the basis for many healthcare 
improvement models because ultimately long term health improvement is based on 
choices patients make every day (Elder et al. 1999). In addition to forming the foundation 
for theoretical models, the importance of willingness to change has been empirically 
shown for many lifestyle changes – incorporating exercise into daily routines, abstaining 
from alcohol, and others (Grandes et al. 2008; Jakobsson et al. 2005; Jallinoja et al. 
2007). We posit that health care providers ought to predict patient activation by 
incorporating patients’ “willingness to change,” (a behavioral construct) within our 
model.  It stands to reason that a patient with more (less) willingness to change is more 
(less) likely to change his activation level. More specifically, when a patient has a high 
(low) willingness to change, this is especially predictive at the high (low) end of the 
patient activation scale.  This leads to our next hypothesis:  
 H4 Low: Low willingness to change is stronger predictor of patient activation, 
than high willingness to change, at low activation levels. 
 H4 High: High willingness to change is stronger predictor of patient activation, 
than low willingness to change, at high activation levels. 
 The concept of system neglect adds a behavioral nuance to the signal detection 
theory: the signal strength is only one predictor of future outcomes, but it receives the 
most attention; on the other hand, system context also impacts future outcomes, but is 
often underemphasized (Kremer et al. 2011; Massey & Wu 2005; Mukherjee & Sinha 
2017). More specifically, Massey and Wu (2005) propose that a situation with low signal 
strength and the decision maker’s behavioral preferences lend themselves to an 
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overreaction bias.  That is, patients are biased towards a given decision based on strength 
of signal, while taking into account the amount of variability in terms of the deviation 
from the average signal in the system. Conversely, this bias reverses, i.e. they illustrate an 
underreaction bias (a bias against a decision) when the signal strength is high. Macmillan 
and Creelman (2004) formalize the definition of this bias. Kremer et al. (2011), and 
Mukherjee and Sinha (2017) find support for this theory in explaining forecasting and 
new product recall decisions, respectively.  
 We extend this theory to the patient activation realm and argue that this 
underreaction (or overreaction) bias leads to incorrect understanding of patient activation. 
Because patient centered care includes helping patients gain “the skills and confidence to 
manage their condition” (Bergeson & Dean, 2006, page 2850), healthcare providers need 
to know where patients are in terms of motivation and understanding (Dixon et al. 2009; 
Shively et al. 2013). Incorrect predictions, especially those that fail to account for 
systematic overreaction or underreaction, can lead to suboptimal choices in the TECC 
process. We note that the postulated underreaction/ overreaction bias is not an artifact of 
the prediction algorithm, but rather it is created by the patient’s willingness to change. 
That is, the prediction itself does not create a systematic bias, but rather, having a high or 
low willingness to change drives the predicted overweighting or underweighting in 
opposite directions.  Thus, we postulate: 
 H5 Low: At lower levels of patient activation, predictions will show an 
overreaction bias at low levels of willingness to change. 
 H5 High: At higher levels of patient activation, predictions will show an 
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underreaction bias at high levels of willingness to change. 
Field Study 
Design of Experiment  
We set up a data collection effort to test our hypotheses using a controlled, randomized 
experiment.  For this experiment, we focused on patients discharged from nine hospitals 
in the greater Indianapolis, Indiana metropolitan and surrounding areas who had a 
primary discharge diagnosis of congestive heart failure (CHF) and/or chronic obstructive 
pulmonary disease (COPD) — common chronic diseases that require significant patient 
self-care (Artinian et al. 2002; Bourbeau et al. 2003) and reflect high (> 20%) hospital 
readmission rates (Jencks et al. 2009). After recruiting and randomizing patients, we had 
95 control patients and 74 intervention patients. (See Appendix 2 for more details.) There 
were no statistical differences between the control group and the intervention group in 
regard to age, race, or health status (See Appendix 2, Table A.1). The intervention group 
received TECC intervention (described in the next section) for 30 days. Both groups 
received routine follow-up care after hospital discharge and were asked to answer the 
patient activation measurement (PAM) instrument after 30 days.  
 Continuity of care can be segmented into three broad areas of continuity: 
informational, managerial, and relational (Haggerty et al. 2003).  When care providers 
track and share data related to a specific patient and their condition (informational 
continuity), use a consistent and appropriate approach to caring for a person and their 
condition (managerial continuity) and consistent people caring for a patient (interpersonal 
continuity), better health outcomes are more likely than when only one continuity exists 
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(Guthrie et al. 2008; van Servellen et al. 2006). Thus, we combined all three types of 
continuity of care in our intervention.  
 Our intervention included sharing objective information (for example, blood 
pressure, weight, whether the patient was experiencing swelling or not) daily through a 
telemonitoring device that electronically maintains this data, thus providing informational 
continuity.  Periodic video conference calls with a healthcare provider, (3 the first week, 
2 the second week, 1 the third week) conducted using telemonitoring technology 
provided both managerial and interpersonal continuity. Because the same healthcare 
provider called a given patient, there was interpersonal continuity. The healthcare 
provider and patient established a therapeutic relationship so they better understood and 
trusted each other. These teleconferences enabled the healthcare providers to assess the 
patients’ status; during the teleconferences, the healthcare provider reconciled the 
medication (asking the patient to show the healthcare provider the medications they had, 
comparing them to what they should have, making sure the patient knows how and when 
to take them) and addressed patients’ concerns during the recovery period. The 
technology enhanced the productivity of these calls because healthcare providers could 
incorporate both the passive objective data (e.g., vital signs and health questionnaire 
responses) and the patient’s facial expressions, breathing and other body language. For 
example, if a patient’s data showed an increase in blood pressure, the healthcare provider 
might ask what the patient has been eating and help the patient understand how eating a 
hot dog directly affected blood pressure. The healthcare provider followed a consistent 
protocol, thus enabling managerial continuity. For details of the protocol, see Appendix 2.   
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Dataset  
We collected the following information about our patients: patient activation, number of 
hospital readmissions, insurance type, and the hospital the patient was discharged from. 
The details are described next, along with how we used these data to operationalize our 
variables.  
 To assess patient activation, we used the 13-question Patient Activation Measure 
(PAM) survey, a validated, uni-dimensional, proprietary instrument measuring patient 
activation (Hibbard et al. 2005). The survey includes questions on patients’ self-
perceived ability and motivation to care for their own health. Patients were asked to 
complete this survey by phone from 30 to 60 days post discharge. We attempted calling 
the patient five times without making contact before classifying a patient as a non-
respondent.  Based on their PAM scores, patients were then classified into one of four 
patient activation levels from not activated (“the doctor is in charge”) to highly engaged 
(“I’m my own best healthcare advocate”). 
 Additionally, the Indiana Health Information Exchange provided readmission data 
(30 days post-discharge) for our patients. 30-day readmission rates are an increasingly 
important healthcare operation metric (Helm et al. 2015; Senot et al. 2016) because the 
US government (through CMS) views such re-hospitalizations as a quality failure and as 
such, under the 2010 Patient Protection and Affordable Care Act, levies penalties for 
hospitals with high readmission rates (PPACA 2010). 
 Multiple characteristics have been shown to influence a patient’s “willingness to 
change” (Glanz et al. 1994; Grandes et al. 2008; Rask et al. 1994; Steptoe et al. 2000).  
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Consistent with this literature, we operationalize our “willingness to change” variable on 
three patient characteristics - whether or not they were a senior (age 65+), whether or not 
they had a low socio-economic status (SES), and whether or not they went to an urban, 
public hospital (Glanz et al. 1994; Grandes et al. 2008; Rask et al. 1994; Steptoe et al. 
2000).  
 The research on seniors’ willingness to change offers mixed findings. Some 
research shows older adults change their health habits at the same rate (or faster) as 
younger adults, and this can be explained by seniors’ low tolerance for risk and their 
nearness to poor health habits’ consequences (Fries et al. 1992; Leigh et al. 1992). Other 
research shows that older patients are less likely to change habits, including health-
related habits, than younger patients (Cole et al. 2008; Grandes et al. 2008). Given that a 
key requirement for self-care is the ability to form new habits (e.g., diet, exercise), and 
shed old habits (e.g., smoking, sedentary lifestyle), the range of changes needed is broad.  
Thus, we posit that senior patients are less likely to change their behavior to create these 
new habits than younger patients.  
 Patients in our sample were treated in one of nine different hospitals, including a 
public, urban hospital. We use this variable because public urban hospitals tend to serve 
as a safety-net for low-income patients (Regenstein et al. 2005), tend to have less 
funding, be located in high-crime neighborhoods, and operate more chaotically than 
private and suburban/rural hospitals (Gourevitch et al. 2008). Patients likely to present at 
these hospitals tend to delay seeking care or not seek care altogether, because of a variety 
of challenges (Rask et al. 1994).  Specifically, not only do they typically have lower 
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quality health insurance, but also they also usually have fewer sick-day benefits to seek 
medical care and fewer daycare options for children, and rely more heavily on public 
transportation (Rask et al. 1994). Thus, patients presenting at these hospitals overcome 
barriers to seek care and must either be in dire need of healthcare and/or particularly 
motivated to get better. The health belief model posits that in order for patients to make a 
change in their health habits, they must feel a need to take action and feel threatened by 
their current health habits (Rosenstock et al. 1988). Patients presenting at urban, public 
hospitals feel threatened enough to seek care, and thus are likely to have a high 
willingness to change. Similarly, patients with low socio-economic status have similar 
challenges and similar motivation. 
 We inferred these patient characteristics (senior status, hospital attended, socio-
economic status) through patient insurance type.  We assigned “senior” status (age 65+)  
(“1”) for patients with Medicare insurance and “non-senior” status (“-1”) for those 
without Medicare. We indicated whether patients were treated at this urban hospital (“1”) 
or not (“-1”) by patients’ insurance type—this hospital was the only one of the nine that 
accepted a hospital specific insurance plan. We classify our study subjects based on 
socio-economic status and assume that patients with Medicaid have low socio-economic 
status (“1”) and those with other insurance types do not (“-1”).  (Many patients have 
several insurance carriers: a patient can be classified as both low socio-economic status 
and age 65+ status by having both Medicaid and Medicare.)  
 Using the three characteristics, namely the dummy variables for whether or not 
each patient 1) attended the urban hospital, was a senior, and had low socio economic 
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status, and based on principle component analysis, we find a single component can 
describe the “willingness to change” variable with the following factor loadings: 
0.821*(Urban Hospital dummy)+(-0.67)*(Senior dummy)+0.691*(Low Socio Economic 
Status dummy). The resulting willingness to change variable ranges in value from -1.5 to 
+1.5.  Because we hypothesize how a low versus high willingness to change variable 
affects prediction of PAM, we then divide this construct into three groups: low 
willingness to change (33.33% lowest scores), medium willingness to change (33.33% 
middle scores) and high willingness to change (33.33% highest scores). 
 Finally, we operationalize signal strength through use of technology-enabled 
continuity of care as a dichotomous variable.  
Analysis 
 We have conducted our analysis in two stages. First, we set up a mediation study 
to test H1, H2a and H2b by performing a set of regressions, which proposes 
interrelationships between TECC, a dichotomous variable, PAM, a continuous variable, 
and our outcome variable, readmissions, a dichotomous variable. Second, we develop our 
prediction model for PAM to test H3, H4 and H5.   
 In the first stage, consistent with mediation model norms (Hayes 2013; 
Wiedemann et al. 2009), we deploy bootstrapping to develop 95% confidence intervals 
around the key estimate to reject the null hypotheses that these estimates can take a zero 
value. We first test H1, i.e., the relationship between TECC and PAM (our proposed 
mediator) using a linear regression model (Model 1) and test if b11 is zero. Next, we test 
H2a, i.e., the TECC- PAM – readmissions mediation model (see Figure 11, panel A) 
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using a logistic regression model with TECC as the independent variable, PAM as the 
mediator, and readmissions as the dependent variable (Model 2). To complete the 
assessment of H2b, we test the moderated mediated model (see Figure 11, panel B/ 
Model 3), as described in Hayes (2013).  We specify models 1, 2, and 3 in the following 
way: 
Model 1: PAM = b10 +  b11TECC + e1 
Model 2: ln (Readmission odds)= b20 + b21TECC + b22 PAM + e2 
Model 3: ln (Readmission odds)= b30 + b31TECC + b32 PAM + b33 PAM*TECC + e3 
Where PAM is the measured activation level, TECC is a binary variable with a 1 
indicating the patient had the TECC treatment, and 0 indicating they did not, and e1, e2 
and e3 are the error terms. 
 In the second stage, we predict the patients’ activation levels. To do so, we first 
defined the classification boundaries and then explored prediction options for each 
boundary. Since the PAM scale is cumulative (Hibbard et al. 2005), we examined three 
classification boundaries: whether the patient was in level 1 versus levels 2,3, and 4; 
levels 1 and 2 versus levels 3 and 4; and levels 1, 2, and 3 versus level 4. With these 
classification boundaries, we ran predictions using two methodologies—a traditional 
logistic regression and a linear support vector machine (SVM) (Anderson et al. 2015). 
We compare these methods in the Appendix 2.   
 A direct comparison of logistic regression and SVM findings requires a choice of 
selection criteria. We elect to use the total error percentage as the relevant criteria for this 
paper. SVM separates data into two classes by constructing a hyperplane using a set of 
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training data so that when new data is added, the SVM characterizes the data in one of the 
two classes. A successful hyperplane has a larger margin between the hyperplane and 
nearest training set data point, as a larger margin means the training points associated 
with each class are further apart, resulting in fewer misclassifications (Cortes & Vapnik 
1995).  
 We next decided on the type of SVM and training set size to use. We selected a 
linear SVM over a Gaussian or polynomial SVM due to the increased total error rate that 
occurred when we utilized a nonlinear SVM; the average error for the Gaussian SVM 
was 1% greater than a linear SVM, and a 2nd order polynomial SVM had an average error 
rate 20% higher than a linear SVM for the same training set size (all other order 
polynomials had higher average error rates) (see Appendix 2). In addition, we looked at 
multi-class support vector machine, but this also produced larger average error rate 41% 
higher than with a linear support vector machine (see Appendix 2).  One explanation for 
this larger error rate is that a multi-class SVM uses a smaller training set size, owing to 
heterogeneous sample sizes for activation levels, than three separate SVMs.   
 We initially ran predictions using seven training set sizes (30, 35, 40, 45, 50, 55, 
60) for both the logistic regression and linear SVM. Comparing results between logistic 
regression and SVM, we found SVM produced smaller classification error across all 
training set sizes. To determine the best training set size, we assessed the average cross-
validation loss for each training set size, a method for determining the accuracy of the 
prediction produced from the training set, by examining the smallest loss (or mean 
squared error) generated (Kohavi 1995). Using this method, the highest accuracy came 
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from a training set size of 45; relevant cross-validation losses are shown in Table 6. We 
also considered a k-fold Cross Validation Loss and a Leave-One-Out Cross Validation 
Loss, and both confirmed that the optimal training set size would be of size 45 (see 
Appendix 2). 
Table 6: Cross Validation losses with SVM Analysis 
Training set size 30 35 40 45 50 55 60 
Average cross 
validation loss 
(%) 
0.256 0.256 0.246 0.245 0.251 0.246 0.250 
 
 For both our SVM predictions and logistic regressions, we determined the total 
percentage error, type I and II errors, and the coefficients or feature weights associated 
with each variable. To classify patients into the lowest patient activation level (1) versus 
the higher levels (2, 3, 4), we could (i) accurately classify a patient as a “1”, (ii) 
accurately classify a patient into the higher group if the patient is a “2”, “3”, or “4”, (iii) 
make a Type I error (classify the patient as a “1” when he/she is a “2”, “3”, or “4”) or (iv) 
make a Type II error (classify the patient as a “2”, “3”, or “4” and when he/she is a “1”). 
Essentially, these possibilities indicate whether we can correctly detect the underlying 
patient activation level or not. In this prediction, we assess whether our model is biased to 
favor Type I or Type II errors. To understand this phenomenon, we calculate detection 
bias (c) given by 
𝑐 =  𝑇𝑦𝑝𝑒 𝐼 𝐸𝑟𝑟𝑜𝑟 − 𝑇𝑦𝑝𝑒 𝐼𝐼 𝐸𝑟𝑟𝑜𝑟2 . 
		
79 
 If c = 0, then we balance the possible incorrect classifications. Consistent with 
Macmillan and Creelman (2004) and Mukherjee and Sinha (2017), when c > 0, an 
overreaction occurs and when c < 0, an underreaction occurs.    
  To determine these values, we ran each test for the three classification boundaries 
for each training set size for 25 iterations, and calculated an average value for these 25 
iterations. For each iteration, a new, randomly sampled training set of size n was created 
and used, with the test data being the remaining data of size, N-n, as the training set data 
is removed. Once the iterations were completed, we compared our SVM results to those 
from the logistic regression (these results are available in the Appendix 2). We found that 
for a training set of 45, that the total error, Type I error, and Type II error, were less for a 
linear support vector machine compared to the logistic regression, which resulted in 
higher total classification errors compared to the SVM, (for details, see Appendix 2). 
 We separated the learning results into two types—the first concerned Type I 
errors, Type II errors, detection biases, and total classification errors.  The second 
concerned the variables’ feature weights. The feature weights for the linear SVM derive 
from the hyperplane; the absolute magnitude of the feature weight indicates a variable’s 
relative importance compared to others resulting from the separation of the two classes. 
Feature weights are similar in their relative magnitude to variable coefficients estimated 
by logistic regression (that are shown in Appendix 2, Table A.3). Since the total errors are 
larger with logistic regressions versus SVM analysis, we selected a linear SVM with a 
training set size of 45 to test our hypotheses.  
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Results 
Tests on Hypotheses H1, H2a and H2b 
Using bootstrap analysis (1000 runs), we test hypotheses 1, 2a and b. We report the 
analysis results as a 95% confidence interval of regression coefficients. The null 
hypothesis in each case stipulates that the regression coefficients equal 0, and if our 
confidence intervals do not contain 0, then we find support for the hypothesis. Regressing 
PAM on TECC, Table 7 shows a positive and significant relationship between TECC and 
PAM (b11= 0.36, 95% confidence interval: 0.18, 0.56), supporting hypothesis 1: a rise in 
the level of TECC increases patient activation through error correction by healthcare 
providers.   
Table 7: Regression results for Model 1 (dependent variable is PAM) 
 Coefficient for Model 1 (95% Confidence interval) 
Intercept 2.77*  (2.41, 2.78) 
TECC 0.36* (0.18, 0.56) 
*= significant at the 0.05 level. N = 118, c2= 10.82; McFadden adjusted R2 = 0.06. 
 Hypotheses 2a and 2b predict a mediated path between TECC, PAM, and 
readmissions, and a conditional moderated mediated path between TECC, PAM, and 
readmissions, respectfully.  Both models show adequate fit, but the moderated mediation 
model has a higher McFadden adjusted R2, suggesting the moderated mediation model 
has a higher explanatory power. Thus, we use this model for assessing hypothesis 2.  
 Results in Table 8 show a negative and significant relationship between TECC 
and the logit of readmissions (b31 = -2.88, 95% CI: -3.15, -2.56), and a positive and 
significant relationship between PAM and the logit of readmissions (b32= 0.67, 95% CI: 
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0.60, 0.74).  Finally, we see a significant relationship between the interaction of TECC 
and PAM and logit of readmissions (b33= 0.43, 95% CI: 0.32, 0.52), which supports the 
moderated mediated model.   
Table 8: Regression results for Models 2 and 3 (dependent variable for both is 
readmissions) 
 Coefficient for Model 2 – 
Mediation model 
(95% Confidence interval) 
Coefficient for Model 3 –  
Moderated Mediation model 
(95% Confidence interval) 
Intercept -2.09 * 
(-2.09, -1.94) 
-2.07 * 
(-2.07, -1.92) 
TECC -1.40 * 
(-1.51, -1.31) 
-1.67 * 
(-1.78, -1.58) 
PAM 0.76 * 
(0.72, 0.82) 
0.67 * 
(0.60, 0.74) 
TECC*PAM  0.43 * 
(0.32, 0.52) 
*= significant at the 0.05 level. N = 118, c2 Mediation= 4.45; McFadden adjusted R2 Mediation= 0.13; c2 
Moderated Mediation= 3.99; McFadden adjusted R2 Moderated Mediation= 0.15. 
Tests for Hypotheses 3, 4 &5 
Table 9A shows support for hypotheses H3 & H4 Low and High. Hypothesis H3 posited 
that using TECC is strongly associated with predicting patient activation levels; the 
feature weight associated with TECC has the largest magnitude, compared to those 
associated with low willingness to change and high willingness to change, for each 
boundary (0.08 for separating between level 1 and the other levels, 0.60 for separating 
between levels 1 and 2 versus 3 and 4, and 0.13 for separating between levels 1, 2, 3 
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versus level 4), supporting hypothesis H3. We show support for hypothesis H4 Low: A 
low willingness to change is a stronger predictor of patients in the lowest PAM level than 
a high willingness to change (0.033 versus 0.013 at lowest activation boundary). 
Conversely, we show support for H4 High: a high willingness to change is a stronger 
predictor of patients in the highest PAM level than a low willingness to change (0.099 
versus 0.021 at highest activation boundary).   
Table 9: (A) SVM Feature Weights Table and (B) Error Assessments 
(A) 
 
Level 1 v. 2,3,4 
(Lowest 
activation 
boundary) 
Levels 1,2 v. 3,4 
(Middle 
activation 
boundary) 
Levels 1,2,3 v.4 
(Highest 
activation 
boundary) 
Comment 
TECC 0.080 0.600 0.128 Supports H3 
Low willingness 
to change 0.033 0.080 0.021 Supports H4 
Low and H4 
High High willingness 
to change 0.013 0.040 0.099 
 
(B) 
 
Level 1 v. 2,3,4 
(Lowest 
activation 
boundary) 
Levels 1,2 v. 3,4 
(Middle 
activation 
boundary) 
Levels 1,2,3 v. 4 
(Highest 
activation 
boundary) 
Comment 
Total Error (%) 0.117 0.339 0.285  
Type I Error (%) 0.113 0.263 0.148  
Type II Error (%) 0.059 0.384 0.271  
Detection Bias (c) 0.027 -0.060 -0.061 
Supports 
H5 Low and 
H5 High 
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 The detection biases in Table 9B show support for hypotheses H5 Low and High. 
Hypothesis H5 Low posited an overreaction bias at the lowest classification boundary 
and H5 High posited an underreaction bias at the highest classification boundary. 
Considering that a positive (negative) bias (c > 0) corresponds to overreaction 
(underreaction), we find an overreaction bias of 0.027 when separating patients at the 
lowest boundary (between level 1 versus levels 2, 3 and 4) and an underreaction bias of -
0.061 when separating patients at the highest boundary (between levels 1,2, and 3 versus 
level 4).  
Robustness Checks 
We have conducted a series of robustness checks, including k-fold cross-validation, 
Receiver Operating Curves, and bootstrap analysis. Our first tests examined whether k-
fold cross-validation was the best method to determine the optimal training set size.  To 
do this, we examined the cross-validation losses using a leave-one-out method.  This 
method confirmed that a training set size of 45 produced the smallest losses (see 
Appendix 2).  
 In order to demonstrate the robustness of our SVM predictions, in addition to our 
error rates shown in Table 9B, we also examined the Receiver Operating Curves (ROC) 
curves for each classification boundary to ascertain that the area under these curve (AUC) 
is larger than 0.5. This measure confirms that the probability that each a binary classifier 
will perform better than randomly assigning data points to different classes (see Appendix 
2). We also performed bootstrapping analysis to show prediction intervals (see Appendix 
2). Results show that the TECC variable is the only variable where the entire confidence 
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interval is positive, indicative of a non-accidental relationship between the TECC 
variable and PAM scores. The confidence intervals associated with the TECC variable 
are all positive, meaning there is a strong association with TECC at each classification 
boundary. This finding is understandable, as it is associated with the predictor variable 
that has the strongest association with each divide according to its feature weight (as 
shown in Table 9A). This simulation confirms that by combining the three variables in 
our prediction model, we have reported a robust PAM prediction, however, individually 
none of these variable have the requisite predictive power. 
 
Discussion  
Moderated Mediation Effect of PAM 
To better understand the interaction term and its meaning, we graph the odds of 
readmissions at low (-1 SD) and high (+1 SD) PAM, and with and without use of TECC, 
in Figure 13.  The figure shows a) those with TECC have lower odds of readmission than 
those without TECC, and b) an increasing probability of readmission as PAM increases.  
While the first is consistent with our theoretical reasoning, the second conclusion 
showing that higher PAM are associated with reduced outcomes is also consistent with 
CHF and COPD literature in the following way.  	  
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Figure 13: Impact of PAM and TECC on probability of readmission 
 
 
 We have a sick patient population: all of our patients were hospitalized for either 
congestive heart failure or chronic obstructive pulmonary disease.  Furthermore, our 
patient population had, on average, a Charlson comorbidity index of at least 3 (See 
Appendix 2, Table A.1) indicating patients at high risk (Charlson 1987). COPD and CHF 
literature shows that those with more serious and/or immediate health problems are more 
likely to be more actively engaged in their health (Artinian et al. 2002; Bos-Towen et al. 
2015; Cameron et al 2009; Riegel et al. 2007).  Thus, we have two competing factors 
driving patients towards higher patient activation. Our hypothesis 1 results show a strong 
relationship between use of TECC and levels of patient activation.  Thus, TECC can help 
those that are interested in increasing patient activation.  Those that have the highest 
probability of being readmitted to the hospital (the sickest) also have the most immediate 
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drive to get better, and thus are highly motivated.  Hence, our results show that TECC 
can help improve patient activation and patient activation drives explanation of 
readmissions.  However, the relationship is suppressed, as some of the sickest patients are 
most likely to actively work to increase patient activation.  Even though they are more 
activated, they are also more likely to be readmitted because of their complications. 
 Another relationship to note is the impact of TECC at different levels of PAM. 
Because the interaction term of PAM*TECC is significant (see Table 8, Model 3), we 
know the impact of TECC is different at different levels of PAM.  Figure 13 shows when 
TECC is used, the probability of readmission increases from 0.01 (PAM = -1 SD) to 0.07 
(PAM = +1 SD), meaning an increase of 0.06 over 2 standard deviations, or a slope of 
0.03.  Similarly, with no TECC, the probability of readmission increases from 0.06 to 
0.20, yielding a slope of 0.07.  This shows with TECC, patients increase their probability 
of readmission at a significantly slower rate than without TECC. This can be translated to 
mean that when a patient is actively engaged, and has the benefit of a healthcare provider 
coaching them to better understand and reach goals; the impact is much greater than those 
without a healthcare provider coach. Indeed, it shows the complementary nature of an 
activated patient, receptive to both healthcare provider feedback and to a changed 
mindset.  
Bias 
Our findings will impact implementation of a controlled study involving patient 
activation because of prediction bias, defined as, “when the criterion score predicted from 
the common regression line is consistently too high or too low for members of the 
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subgroup” (Cleary 1968, page 115). As findings in Table 10 confirm, our prediction 
results are indeed uneven in terms of the probability of outcomes associated with the 
disaggregated distribution of independent variables (i.e. patient variables at levels 1 
versus levels 2,3, and 4, etc.). It has been shown that conventional analysis (logistic 
regression) does a poor job of correcting for these selection biases, whereas SVM 
regression results are robust because selection bias at any level does not affect hard 
margin SVM (Zadrozny 2004). This is also discussed in Appendix 2, Table A.2).  
 
Table 10: Posterior Probabilities of Predicting PAM 
 
Level 1 v. 2,3,4 
(Lowest 
activation 
boundary) 
Levels 1,2 v. 3,4 
(Middle 
activation 
boundary) 
Levels 1,2,3 v. 4 
(Highest 
activation 
boundary) 
TECC 0.88 0.78 0.63 
Low willingness to change 0.89 0.72 0.56 
High willingness to change 0.88 0.68 0.60 
 
  Additionally, we examined the posterior probabilities of positive outcomes on the 
inclusion of each independent variable (IV) to which we add a feature weight, while 
holding all other IVs constant (Platt 1999). Table 10 presents the results; the rows show 
the independent variables (IV) and the columns list the classification boundaries. The 
table cell values indicate the probability of a positive inclusion of the IV. For example, if 
a person was part of the intervention group, they have an 86% chance of being classified 
into the 2, 3, 4 group as opposed to the 1 group, ceteris paribus. These probabilities 
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decrease due to Guttman scaling of the PAM, (i.e., cumulative property of the PAM) 
(Hibbard et al. 2005); if a patient belongs to level “i” on the PAM scale, he/she must also 
have the skills and knowledge within the level “i-1.” Thus, the lowest classification 
boundary (PAM level 1) shows the highest probability outcome. 
 An additional implication is based on hypotheses H5 Low and H5 High for biases 
featuring predictions at the lower and higher activation classification boundaries.  We 
note these biases reverse their sign as the classification boundary shifts from lowest 
separation (level 1 versus 2, 3 and 4) up to the highest classification boundary (level 1, 2, 
and 3 vs. 4). Hence, we argue that the observed biases reported in Table 9B and their 
signs is an artifact of the dataset, rather than the prediction algorithm. The 
implementation implications of the bias related findings are that if the healthcare system 
uses such predictions to inform their continuity of care hospital discharge protocols, in 
aggregate, the predictions exhibit underestimation and overestimations at the two ends of 
the reporting scale. This implies that when predicting the separation between levels 1, 2 
versus levels 3, 4, the system exhibits minimal bias. On the other hand, at separation 
between level 1 versus levels 2, 3, and 4 (or levels 1, 2, and levels 3 v. 4) prediction of 
patient activation exhibits an over-estimation (under-estimation) bias that must be 
corrected by the healthcare providers. 
Theory Implications 
Our study posits a learning framework (i.e., a controlled study followed by prediction of 
behavioral outcomes in controlled TECC interventions). From a theory perspective, we 
add to the formulation of system neglect driven detection of signals (Massey & Wu 
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2005), by isolating the twin mechanisms that influence the patient activations into double 
loop learning framework: (i) a loop that creates a channel for exchanging information 
signal between the patient and healthcare provision system, and (ii) a second loop that 
captures the creation and reinforcement of the mental model for the patient in terms of his 
/her willingness to change. This structure allows us to isolate the signaling effect and the 
behavioral bias in a controlled study.  
 We note that the interpretations of weights, and allied estimated biases, is 
receiving attention in terms of fairness and gaming behavior, based on predictions driven 
by demographic factors, in the machine learning literature studies conducted in the cyber 
security context (Datta et al. 2017). In parallel, there is growing interest in using 
personalized technology to provide interventions specific to a patient’s context to support 
healthier behaviors (Hu et al. 2018).  Thus, it ought to be possible to introduce additional 
constructs that affect weights and refine the biases associated with patient activation to 
profile the patient. Allied possibility of gaming (between the healthcare providers and the 
patient), and potential for fairness in handling patients are issues that we identify as an 
avenue for follow on research. 
 From an empirical standpoint, the prediction results could be applied more 
generally to inform controlled studies in other engagement areas by altering variables 
suitably. For instance, a potential study could look into medical adherence in the HIV 
population while augmenting the patient care input variables, such as signal strength, 
with additional constructs, such as capacity of patient care facilities (McCoy & Johnson 
2013). In such a study, patient behavioral variables, such as willingness to change, could 
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be extended with additional behavioral constructs, such as forgetfulness (Chesney et al. 
2000). It might also be possible to inform the design of the controlled study in real time 
with better estimates of demand based on outcomes of the machine learning analysis (see 
Bertsimas et al. 2016, for a discussion of related ideas). These are potentially useful ways 
to extend and to implement our framework. 
TECC Process Improvement 
We note that the healthcare providers in the TECC intervention received daily updates 
from their patients through the equipment. These updates included objective readings 
(e.g. blood pressure, weight, etc.) and perceptive measures (e.g. extent to which patient 
felt tired or short of breath, etc.).  However, due to the pre-specified nature of our 
experimental design (i.e. IRB approval mentioned in Appendix 2), we did not track such 
fine grained data, but suggest such data could better support our learning framework. We 
therefore deem this to be a proof-of-concept study for our theory framework and restrict 
our claims to this study as additional theoretical analysis and field studies are needed 
before the proposed framework can be generalizable. For instance, the healthcare 
providers concentrated teleconferences in the start of the month long continuity of care 
process (three contacts in week 1, two in week 2 and one in week 3). Healthcare 
operations models have examined dual causality between patient medical adherence and 
optimal resource allocation (McCoy & Johnson 2014). We posit that a similar analysis is 
also feasible using the predicted PAM data. In such a setting, asking what is the most 
effective schedule (e.g., front- versus back-loaded) and its impact on allocation resources 
based on perceived distribution of activation levels raises a useful theoretical question. 
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We also note that the model does not account for the degradation of patient condition in 
the period of observation as has been shown in the literature (Bavafa et al. 2015; Deo et 
al. 2013). We justify this shortfall based on the fact that the readmission rates in the 
control population, are relatively low (10.5%). A longer time horizon may lead to higher 
readmission rates and call for explicit modeling of the patient’s deterioration during the 
period of observation. Scheduling of healthcare providers and patient deterioration 
provide future research opportunities.  
Limitations 
This study has several limitations. Some variables were observed but not measured 
(because they were not in the IRB-approved design), and thus were not incorporated into 
the learning prediction model. For instance, patients reported their vital conditions daily, 
which were observed by the healthcare providers but not incorporated into the dataset. 
Similarly, some patients visited their health care providers during the 30-day observation 
period, but we did not collect this data. Also, the learning framework alludes to observed, 
but not measured constructs (e.g., self-care decisions and exact schedules for the nursing 
care provided), which could be documented to provide a firmer baseline for further 
analysis. Additionally, we collected patient activation data after our intervention; future 
researchers may want to collect this data pre and post intervention. This data suffers from 
attrition bias in that the intervention group had a much higher response rate (93.2%) 
versus the control group (51.6%).  Although a higher response rate from the control 
group would have been preferred, the combination of improved PAM scores, coupled 
with readmission rates provides complementary data supporting the efficacy of the 
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intervention.   
 Another limitation is our operationalization of “willingness to change” - a 
combination of three patient characteristics: senior status, low socioeconomic status, and 
admittance to a public, urban hospital. While these characteristics have general, 
theoretical ties to willingness to change, expanding the measurement to include other 
important characteristics, such as social support (Dickson et al. 2013; Steptoe et al. 
2000), could improve accuracy.  Additionally, others have used a specific scale to 
measure “stage of readiness”, translating to five distinct levels of prepardeness for 
change, from pre-contemplation through to action and maintenance (Morera et al. 1998; 
Steptoe et al. 2000).  This, more targeted measurement, could improve results as well.   
Conclusion 
 In order to assess the relationships among TECC implementation, enhanced 
activation and the detailed decisions made within a healthcare provision system, we 
developed a double loop-learning framework and tested five related hypotheses. Using 
this framework, we establish a relationship between the use of TECC and an increase in 
patient activation levels. The singular contribution of our work, compared to existing 
literature (e.g. Shane-McWhorter et al. 2015), lies in the use of a learning framework to 
show that SVM can predict patient activation levels as a function of the strength of the 
information signal and the patient’s willingness to change. We find that these are subject 
to under/over estimation biases that are consistent with system neglect theory. This is, 
however, a proof-of-concept study that establishes the potential for using TECC in the 
patient-centric healthcare context to predict and enhance activation (i.e., patient 
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engagement). We conclude by identifying a series of follow-up studies that could hasten 
the implementation of the proposed technology to simultaneously improve patient 
outcomes and healthcare operations needed for enhancing patient activation.
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CHAPTER FOUR: UTILIZING DATA-DRIVEN DECISION SUPPORT 
SYSTEMS TO REDUCE READMISSION RATES FOR PATIENTS WITH 
CONGESTIVE HEART FAILURE 
Introduction 
 Hospital readmissions are used as an indicator of health system quality and 
performance. Public payment systems such as Medicare and Medicaid utilize condition-
specific readmission rates to penalize health systems when their rates are higher than the 
national expected risk-standardized 30-day readmission rate for that condition. 
 The Hospital Readmission Reduction Program (HRRP), established as part of the 
Affordable Care Act in 2012, looks at readmission rates for three particular conditions – 
pneumonia, myocardial infarction, and congestive heart failure (CHF) (Mcllvennan et al. 
2015). In 2011, the Centers for Medicare & Medicaid Services (CMS) has acknowledged 
that readmissions for patients initially hospitalized due to CHF are both the most 
common form of Medicare patient readmissions in the United States (with the number of 
all-cause readmissions for 2011 being 134,500 – or 7.3% of all Medicare Readmissions) 
and the most costly to the hospital (costing $1.7 billion – or 7.1% of all Medicare 
readmission costs) (Mirkin et al. 2017). 
 As part of the HRRP, hospitals are financially penalized if the number of 
readmissions for CHF patients exceeds a standardized national average, which provides 
further economic burden to a hospital that is already bearing the costs of these expensive 
and common readmissions.  At present, the risk-adjusted median 30-day rate of 
readmission for CHF ranges from 23% to 24.6%, and has led hospitals to impose a 
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number of types of interventions in recent history in order for that number to be reduced 
(Ziaeian & Fonarow 2016; Dharmaraian et al. 2017).  There are legitimate concerns that 
all-cause readmissions may be a poor indicator of care quality, especially in safety-net 
hospitals, however, the emphasis on reducing readmissions has shown improvement in 
overall readmission rates in all hospital systems (Zuckerman et al. 2016; Cary & Lin 
2016).  
 Interventions by healthcare systems to reduce HF readmission range from 
different medical choices (such as evidence-based beta blockers and aldosterone 
inhibitors) to device therapies (such as implantable cardioverter defibrillators).  These 
interventions, along with strategies to increase patient activation, have been put in place, 
and have seen a varied level of results (Felter et al. 2014).  
 Therefore, we can posit that due to the readmission rate for CHF remaining high, 
there is a process problem by which healthcare providers are not accurately identifying 
either high-risk readmission patients, or that the intervention strategies are not effective.  
It comes down to a patient engagement problem, where healthcare providers need to be 
able to communicate a patient-centric care plan to a high-risk patient, but in order to 
accomplish that, they first need to be able to better identify which patients are at risk of 
readmission. 
 However, what is not discussed as deeply in the literature is that there could be a 
third possibility, and that is from the fact that the HRRP looks at “all-cause” 
readmissions.  “All-cause” means that a hospital can be penalized for a patient 
readmission independent of whether the readmission is condition-related or not (Kocher 
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& Adashi 2011).  The reason behind this choice is so that healthcare providers have a 
more holistic focus on a patient’s condition, and it is supposed to encourage hospitals to 
look beyond the patient’s primary medical problem and account for other aspects of a 
patient’s condition, such as psychological or economic problems that could affect either 
treatment or outcome. However, these may be non-avoidable readmissions, as they are 
unrelated to the patients’ conditions, and therefore there is a need for intervention plans 
to be able to focus on avoidable readmissions. 
 In fact, out of all Congestive Heart Failure patients who are readmitted to the 
same hospital within the 30-day period, only 35% of those patients are readmitted for 
reasons related to the condition for which they were initially hospitalized – and this, in 
turn, can be problematic when it comes to the correct application of readmission 
reduction interventions (Mcllvenan et al. 2015). 
 Can we create a statistical model that identifies both the likelihood of a patient 
being readmitted and  also the reason for the readmission? If we can improve the patient 
readmission risk identification process to account for both types of readmission - whether	for	condition-related	reasons	or	not	–	we	can	improve	the	efficiency	of	the	intervention	process,	and	therefore	lead	to	a	reduction	in	patient	readmissions,	and	therefore,	hospital	costs.		 
 In this conceptual paper, we will look at what is needed to develop a statistical 
model utilizing readily available patient-specific information to first predict the 
likelihood of readmission for a particular patient, and how we could compare these 
results to the standard methodology for identifying patients with a high risk of 
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readmission. The second step is then is to determine for these patients who have a high 
likelihood of being readmitted can we further identify whether or not they will be 
readmitted for condition-related reasons.  The goal of this work is to suggest different 
intervention strategies for health care providers for a three-fold purpose: 1) to reduce 
patient readmission, 2) to reduce hospital costs associated with readmission, and (3) to 
improve the efficiency of the intervention process and reduce associated costs. 
Background 
 The work of reducing rates of readmission has been a popular topic in both the 
managerial sciences and in healthcare specific domains.  However, the use of data-driven 
predictive analytics to inform healthcare providers on how to improve their processes is 
also crucial when it comes to accomplishing this goal.  Therefore, for this work, we draw 
on two different literature streams: the study of process improvement to reduce patient 
readmission, and the use of data-driven decision making for problems in the healthcare 
domain. 
Process Improvement  
In order to utilize interventions effectively, we need to understand how different aspects 
of the physician decision-making process affects the ability to reduce the rate of 
readmissions.  The main area in which the healthcare domain has looked at reducing rates 
of readmission is through improvement and standardization of patient discharge 
procedures (Jack et. al 2009).  One method of improvement is through the use of Re-
Engineered Discharge (RED) processes (Greewald et. al 2007).  This 11-point patient-
centric process was introduced to standardize patient discharge procedures, with the goal 
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of reducing avoidable (non-condition related) readmissions, and included components 
such as patient education, pre-scheduled follow up appointments, and confirmation of the 
patient’s understanding of the medication plan.  The goals of each component were to 
improve the patient engagement, and their ability to manage and maintain their own 
healthcare. These discharge process improvement interventions have been proven to be 
effective, lowering readmission rates to 10%, but are only effective with highly engaged 
patients working with a skilled nursing staff who are able to identify high-risk patients 
(Berkowitz et al. 2013).   
 This allows us to see at the highest level that although effective interventions 
exist, they are hindered by the ability to identify the patients that will benefit the most 
from them. 
 In the area of operations management and information systems, there has been 
much work done looking at the relationship between various hospital attributes and the 
rate of patient readmission. 
 This important relationship studied in the literature between hospital conformance 
quality, such as RED processes, and readmission has also been looked at.  There is 
already an understanding of the importance of how the hospitals level of adherence to 
evidence-based standard medical practices can lead to lower rates of readmission, 
especially if combined with an improved patient experience (or experiential quality) 
(Senot et al. 2015; Senot et al. 2016). Standardized processes, along with service quality, 
always have the ability to lead to a reduction of potential adverse events that could lead to 
a potential readmission (Zheng et al. 2017). Understandably, however, any increase in 
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quality also has a corresponding increase in patient cost for the initial hospitalization, and 
this is an important limitation that needs to be addressed.   
 This idea that a reduction is a hospital’s rate of readmission is inevitably 
associated with an increase in cost is a common theme.  Operationally, this is due to the 
way in which hospital’s look at which attributes affect readmission, ranging from 
conformance quality to choices such as the length of stay for the initial hospitalization.  A 
CHF patient’s risk of readmission increases when the initial length of stay decreases 
(increasing 1.1% for a reduction of 1 day), so we can say that length of the initial hospital 
stay is a predictor of readmission risk, as it could relate to the patient receiving less care 
than they require (Oh et. al 2017).  The literature discusses who is making the decisions, 
and how these decisions affect the likelihood of patient readmission, but does not discuss 
how we can identify which patients are those who are likely to be readmitted (Senot et al. 
2015). However, our work needs to look beyond just how a single attribute affects 
readmission, to takes a comprehensive look at how different attributes interact to increase 
this likelihood.   
 There is a gap in the literature about how patient-specific attributes, in 
conjunction with different aspects of the hospital environment or hospitalization process, 
increase or decrease the rate of readmission.  In our work, we make the assumption that 
aspects such as conformance length of stay, and patient health attributes are either 
standardized or out of the physician’s control, and that their decision-making revolves 
around their choices of patient- or condition–specific interventions. 
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Data-Driven Decision Making  
Now that we have established the gap in the process improvement literature that needs to 
be filled, it is important to understand how data-driven decision support systems have 
been utilized to reduce patient readmissions.   
 At present, hospitals have implemented a way in which they can categorize the 
likelihood of patients being readmitted.  Each day during hospitalization, a patient is 
given a LACE score, on a scale of 1 to 19 indicating whether they are at a “high,” 
“moderate,” or “low” risk of readmission based on attributes, such as (“L”) length of 
stay, (“A”) method of admission, (“C”) co-morbidities, and (“E”) their patient history 
prior to hospitalization (specifically how frequently they visit emergency departments) 
(Robinson & Hudali 2017).  High-risk patients would be given additional attention in 
hopes of improving their ability to manage and maintain their own healthcare, and reduce 
unexpected adverse events during hospitalization.  However, this system has not been 
proven yet to reduce patient readmission, and the categorizing for assessing risk is 
anecdotal, and not evidence-based, and is non-condition specific. 
 Therefore, due to the current checklist nature of the healthcare provider decision-
making tools, healthcare information systems literature has started to use data-driven 
optimization techniques to improve these healthcare decision-making processes. 
 At a high-level, our work builds on the work of Saghafian et al. (2013) in that we 
are also creating a model to identify patients based on the likeliness of readmission and 
the effectiveness of different types of medical interventions. Their paper looked at how 
their model can classify patients in order to combat overcrowding in hospital emergency 
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departments and improve performance, by providing decision support for whether or not 
a patient should be admitted or discharged. We take a similar approach with our data, to 
see if our patients can be placed into different intervention strategies dependent on both 
their likelihood, and reason for, admission. Whereas other papers have focused on the use 
of these techniques to improve hospital efficiency, our goal is to be more patient-focused, 
and to use similar identification techniques to reduce patient readmissions. 
 This area of patient-specific treatments and customized medical strategies is an 
on-going and growing field in the area of healthcare information technology literature, 
and is going to look beyond the resource allocation issues previously studied to looking at 
how physicians can customize the service they provide to patients based on attributes 
such as their health status (Bavafa et al. 2013).  Our paper complements these growing 
fields of study by allowing us to take these concepts and apply them to the area of 
physician decision support systems to make patient-specific intervention strategies to 
reduce the likelihood of patient readmission, therefore reducing costs. 
 A major issue at present with data-driven decision support systems is the way in 
which healthcare providers utilize them.  Due to the complex nature of these tools, 
physicians have a tendency to view them as a “black box” (Abbasi & Kashiyarndi 2006).  
This leads to the problem seen in the industry that if the physicians do not understand the 
nature by which these tools “make” their decisions, then they are less likely to trust the 
tools and less likely to use them (Chau & Hu 2001). 
 An important work that exemplifies this issue in the literature, by Bardhan et al. 
(2015), already takes the first step at looking at how predictive analytics can be used to 
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predict the likelihood of a congestive heart failure patient to be readmitted. This work 
takes the first steps in utilizing patient-specific information to answer two key questions – 
whether the patient will be readmitted, and if so, will they be readmitted in under 30-
days.  This is important because if a patient is readmitted, but it is after 30-days, then 
under the HRRP, the hospital will not be penalized.  They utilize their own model 
(known as a beta geometric Erlang-2 hurdle model) and compare their results to a 
standard logit model.  They provide a strong framework for demonstrating model value in 
this domain, but they also leave a space for us to provide a necessary improvement. 
 Their work focuses on the importance of health IT as the intervention, and how 
this leads to lower readmissions in general.  This generality is because their focus is on a 
single condition non-specific intervention to reduce the rates of “all cause” readmission.  
Our work takes this further but not concerning ourselves with the intervention 
effectiveness, but with the readmission type – but also by creating a tool that is accessible 
to healthcare providers.  We have the opportunity to build on this work by creating an 
approachable model for advising physicians on which type of intervention (condition 
specific or not) will the most effective for a particular patient category. 
Context and Data 
 In order to derive a model for identifying both the likelihood of patient 
readmission, and the cause of readmission, we utilize a data-driven approach.  Our 
dataset, from a large, urban, academic hospital, contains entries for 1,188 Medicare or 
Medicaid patients who had been hospitalized over the course of a 13-month period (from 
September 2016 through September 2017) for congestive heart failure.  For every patient, 
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the dataset includes, admission date, length-of-stay, gender, discharge status, age bracket, 
ethnicity, primary language, employment status, patient comorbidities, and reason for 
admission and readmission, if readmitted (MS-DRG codes). The focus on Medicare and 
Medicaid patients is due to the fact that the HRRP penalties, as mentioned earlier, are 
concerned with those particular patient readmissions. 
 The hospital is underperforming compared to its peer institutions, and has 
attempted three interventions over the past seven years in order to reduce readmissions.. 
Although the interventions have led to a 4.7% average reduction in the rate of 
readmission for CHF patients over the period, all interventions were discontinued in 2017 
to focus on deriving a new patient-centric intervention policy.  
 In the dataset, we have 276 readmissions within 30 days of discharge post-initial 
hospitalization, which is 23.2% of the population. Determined from the Medicare 
Severity Diagnosis Related Group (MS-DRG) codes upon readmission, of those 276 
readmitted patients, 165 of them were readmitted for cardiac-related reasons (59.8%), 
compared to 111 patients that were readmitted for non-condition related reasons, such as 
seizures, intracranial hemorrhages, and renal failure. 
 The hospital, at present, does have its own method of identifying high-risk 
patients. Table 11 shows us the list of 15 assessment questions, which allow healthcare 
providers, using Figure 14, to classify patients between “low risk,” “moderate risk,” 
“high risk,” and “super utilizers.” 
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Table 11: Assessment Questions  
Assessment Question Points 
Has the patient had 2 or more readmissions in the past year? 7 
Has the patient had 2 or more ED visits in the past year? 2 
Is activity on admission ‘Bed rest’, ‘Chair’, ‘Turn’ or ‘Commode’? 1 
Is substance use active on admission? 1 
Is the patient currently on dialysis? 1 
Does the patient have sickle cell disease? 2 
Does the patient have CHF?  1 
Does the patient have CAD?  1 
Does the patient have COPD?  1 
Does the patient have active cancer?  1 
Is the nutrition score >1 and has the point lost > 5 lbs or is on TPN or tube 
feeds? 1 
Is patient on an ACEi or ARB on admission, or was it ordered on admission? 1 
Is patient on an opioid as an outpatient? 1 
Is patient on a steroid on admission, or was it prescribed on admission?  
Is patient on anticoagulation on admission, or was it ordered on admission? 1 
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Figure 14: Readmission Risk Assessment Score 
 
 
 As can be seen from Figure 14, this assessment method does allow for the 
hospital to discern that potentially 35% of these CHF patients are at a high-risk of 
readmission, but what it doesn’t allow for is for a condition-specific risk score.  
 Therefore, the hospital has created a task force with the goal of reducing 
readmission by identifying both which patients are likely to be readmitted, but also, for 
which reason.  This will allow them to use targeted and proven effective interventions 
(either similar to a RED process, or one of their own interventions. 
 
Discussion 
Solution Approach 
The goal of this paper is twofold: (1) to provide a statistical model to provides a more 
accurate prediction of whether a patient is likely to be readmitted, and (2) provide a 
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model that will allow us to determine for those patients who are likely to be readmitted, 
can we predict with accuracy whether the readmission is for condition-related reasons or 
non-condition related reasons. 
Prediction of the Likelihood of Readmission 
The first step of the solution of the paper is to provide the healthcare providers, 
particularly nurse practitioners, with a usable decision-making support tool to determine 
whether or not a patient is at “high risk” of readmission. 
 We will use a logistic regression model, using the twelve categorical patient-
specific parameters outlined in the previous section (reason for admission, length of stay, 
gender, ethnicity, occupation, discharge status, age, language, and relevant co-morbidities 
present - heart disease, diabetes, obesity, or hypertension).  Our dependent variable is 
simply if they were readmitted.  In the first stage we are not concerned how long until 
they were readmitted, or their reason for readmission, simply defining them as “high-
risk” of readmission if they were indeed readmitted. 
 We, then, calculate our prediction error relative to those we know who were 
readmitted, and compare that to the hospitals readmission risk assessment error – where 
we say that the hospitals model is in error if they say a patient is “high risk” or a “super 
utilizer” and then is not readmitted. 
 We expect to see an improvement in our model over the conventional model due 
to the hospital’s model’s non-data-driven nature.  In addition, the elegance of the ease-of-
use of our model is that it will allow us to discuss which factors were significant 
predictors, and if they are the ones already discussed in the literature – such as ease of 
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communication and length of stay.  This will give our hospital’s healthcare providers 
insight into which areas, at a high level, should receive the most focus during their 
intervention processes. 
Prediction of the Cause of Readmission 
The second stage of our model is to look at if we can predict the reason for which a 
patient will be readmitted.  
 This will be solved in a two-stage process.  First, taking only the subset of 276 
readmitted patients, we will again, utilize a logistic regression model to predict if their 
readmission is for condition-related reasons or not, and compared to the observed 
outcomes.  Of course, this isn’t a strong predictor, as it makes the weak assumption that 
we can first accurately predict that a patient is going to be readmitted at all. 
 Therefore, the second stage is the use of a multinomial logistic regression model, 
where the base case is that the patient won’t be readmitted, followed by that the patient 
would be readmitted for condition-related reasons, and then for non-condition-related 
reasons.  This allows us to infer: (1) how accurately our model can make these 
predictions, (2) if there is a category where error is more likely to occur, which would 
indicate that more patient-specific information could be needed to make these 
assumptions, or would tell physicians to focus on one readmission condition over 
another, and (3) what are the significant predictors for each cause of readmission, and 
which predictors do they have in common. 
 These models could allow us to determine if the use of this model would allow 
physicians to both reduce readmission rates and reduce costs, as we have efficacy rates 
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and costs for particular intervention strategies (“all-cause” versus condition-specific), 
along with the costs of readmissions for different DRG codes. 
Limitations 
 There are three main limitations to this paper.  
 First, that we may have a bias in the population due to the type of hospital – large, 
urban, academic, and underperforming compared to its peers.  This could be seen in that 
in our population, almost 59.8% of readmitted patients are readmitted for condition-
related reasons, compared to 35% of the national population.  This would need to be 
addressed in the final journal paper for our model to have generalizability. 
 The second comes from the simplicity of our model.  The goal of this paper is to 
provide a model for healthcare providers that can generate useful decision-making 
support.  To overcome this, we will compare our model to more traditional decision 
support system prediction models to make sure our elegance of use doesn’t detract 
significantly from the predictive power of the model. 
 Lastly, our policy analysis looking at the cost reduction potential of our model, 
and the reduction in readmission rate due to our model, would need to be simulated from 
pre-existing data about efficacy of pre-existing intervention policies.  To remove this 
barrier, we will conduct  a follow-up study where our model would be utilized by the 
hospital’s readmission task force that we are working with in order to see if these 
simulated results would hold true.
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CHAPTER FIVE: FINAL THOUGHTS 
 This dissertation delves into how operations management and information 
systems can be used to solve the challenges posed within the healthcare domain when it 
comes to the use of data-driven decision support systems for personalized medicine 
processes. It takes the first steps in demonstrating how operational tools can be used to 
close this gap in the decision support systems literature.   
 Going forward, these collected works provide the grounding for at least two 
future streams of research that should be conducted in order for this work to be able to be 
fully realized in the healthcare domain.   
 This dissertation sets up three robust models for different decision support 
systems, but in order for their robustness to be proved, they need to be applied in 
healthcare situations to demonstrate their efficacy, hence the emphasis in the third study 
of our relationship with the hospital task force, and the next step forward will be to take 
the model derived from that conceptual study and apply it in the hospital setting where 
our data was collected. 
 Secondly, in order for delve as deeply as this dissertation has, these studies have 
all focused on a single condition category, cardiac conditions, and have all been location 
specific. This could argue against the generalizability of these decision support system 
models, as they could be seen as condition- or location-specific.  To counteract this 
thought, one needs to conduct comparative studies – both when it comes to location 
(comparing CHF patients in two different locations in the United States with different 
population demographics) and condition (comparing predictive modeling between two 
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different chronic condition patient groups – those with congestive heart failure versus 
those with diabetes). 
 The successes of these two studies will demonstrate that these studies within this 
dissertation are not only robust theoretically, but also that these models are generalizable 
and applicable to real-world healthcare situations. 	
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APPENDIX 1 
Revenue Neutral Subsidy Calculation 
Definitions: Let ℙ! be the current price of the test; 𝛥! be the subsidy provided to the patients with lower economic status, making the price 
of the test ℙ!𝛥! for them; 𝛥! price increase factor for others, making the cost of the test ℙ!𝛥! for them; 𝛥𝐶! be the expected reduction in disutility for patient 𝑖 if the patient undergoes genomic 
test; ℛ be the set of patients of higher economic status; 𝒫 be the set of patients of lower economic status; 𝑅 be the set of patients of higher economic status who currently decided to test and 𝑛! be 
the size of the set; 𝑃 be the set of patients of lower economic status who currently decided to test and 𝑛! be 
the size of the set; 𝑅! 𝛥! = {𝑖 ∈ ℛ:𝛥𝐶! > 𝜋!ℙ!𝛥!} be the set of patients of higher economic status who 
would undergo the test at the new price of ℙ!𝛥! and 𝑛!! 𝛥!  be the size of this set; 𝑃! 𝛥! = {𝑖 ∈ 𝒫:𝛥𝐶! > 𝜋!ℙ!𝛥!} be the set of patients of lower economic status who 
would undergo the test at the new price of ℙ!𝛥! and 𝑛!! 𝛥!  be the size of this set; 
the disutility of patients in high socioeconomic status: 𝐶! 𝛥! = 𝛥𝐶! −!∈!! !!𝜋!ℙ!𝛥!; 
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the disutility of patients in low socioeconomic status: 𝐶! 𝛥! = 𝛥𝐶! −!∈!! !!𝜋!ℙ!𝛥!. 
The revenue neutrality condition requires the total revenue before any change to pricing 
to be equal to the total revenue after the change. This translates to 𝑛! + 𝑛! ℙ! = 𝑛!! 𝛥! 𝛥!ℙ! + 𝑛!! 𝛥! 𝛥!ℙ! 
Or, 𝑛!! 𝛥! 𝛥! + 𝑛!! 𝛥! 𝛥! = 𝑛! + 𝑛! 
The condition makes 𝛥! and 𝛥! dependent. We define the following function to capture 
the dependency. 
𝛥! 𝛥!,𝑛!! = 𝑛! + 𝑛! − 𝑛!! 𝛥! 𝛥!𝑛!!  
The Revenue-Neutral Subsidy Calculation Problem for Total Disutility 
Minimization (The RNS calculation Problem) 
The total disutility minimization problem under revenue neutral subsidy for patients at a 
lower economic status is:  max!! 𝐶! 𝛥! + 𝐶! 𝛥! Disutility-Reduction Maximization
such that 𝑛!! 𝛥! 𝛥! + 𝑛!! 𝛥! 𝛥! = 𝑛! + 𝑛! Revenue-Neutrality Condition  
Algorithm RNS Finder (ℛ,𝒫, 𝛥𝐶! ,𝜋!,𝜋!) 
1. Define a set to hold potential subsidy and price increase factors: 𝑀 =  {} 
2. Compute 𝛥!,!! = !!!!!ℙ! ∀𝑖 ∈ 𝒫  and 𝛥!,!! = !!!!!ℙ! ∀𝑖 ∈ ℛ  
3. Let ℛ! =< 𝑟!,… , 𝑟 ℛ > be the list of indices that sorts ℛ in the decreasing order 
of 𝛥!,!!  
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4. For 𝑝! ∈ 𝒫 do 
a. Find the pair in 𝑟! , 𝑟!!! ∈ ℛ!:𝛥!,!!! ≤ 𝛥! 𝛥!,!!! , 𝑟! ≤  𝛥!,!!!!!  that 
maximizes 𝐶! 𝛥! 𝛥!,!!! , 𝑟! . Let the price increase factor 𝛥! 𝛥!,!!! , 𝑟!  
for that pair be 𝛥!! 𝛥!,!!! . 
b. Collect the price-factors and disutilities 𝑀 = 𝑀 ∪ 𝛥!,!!! ,𝐶! 𝛥!,!!! , 𝛥!! 𝛥!,!!! ,𝐶! 𝛥!! 𝛥!,!!!  
5. Return the tuple 𝛥!,!!! ,𝐶! 𝛥!,!!! , 𝛥!! 𝛥!,!!! ,𝐶! 𝛥!! 𝛥!,!!! ∈ 𝑀 such 
that 𝐶! 𝐶! 𝛥!,!!! + 𝐶! 𝛥!! 𝛥!,!!!  is the largest in 𝑀 
RNS Proposition:  
The Algorithm RNS finder solves the RNS calculation problem in 𝑂 ℙ ℝ  time. 
Proof: 
Although, 𝛥! and 𝛥! are dependent through the Revenue Neutrality Condition, the 
following two conditional independencies hold: 𝑅! 𝛥! ,𝐶! 𝛥! ⊥ 𝛥!,𝑃! 𝛥! ,𝐶! 𝛥!  | 𝛥! 𝑃! 𝛥! ,𝐶! 𝛥! ⊥ 𝛥! ,𝑅! 𝛥! ,𝐶! 𝛥!  | 𝛥! 
Therefore, for each value of 𝛥! there is a unique value of 𝑃! 𝛥!  and a corresponding 
unique value of 𝐶! 𝛥! . For each value of 𝛥! multiple 𝑅! 𝛥! ,𝐶! 𝛥! ’s might satisfy 
the Revenue Neutrality Condition. However, the specific choice of 𝛥! or values of 𝑅! 𝛥! ,𝐶! 𝛥!  does not affect the 𝐶! 𝛥!  due to the conditional independence. 
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Therefore, the price-increase factor 𝛥!! 𝛥! = argmax!!∈!! !! 𝐶! 𝛥!  maximizes the 
total reduction in disutility 𝐶! 𝛥! + 𝐶! 𝛥!  for the 𝛥!. Hence, it follows that the value 
of 𝛥! that maximizes 𝐶! 𝛥! + 𝐶! 𝛥!! 𝛥!  maximizes 𝐶! 𝛥! + 𝐶! 𝛥!  over all 
possible values of 𝛥! and 𝛥! — solving the RNS calculation problem. 
The complexity of the Step 3 is 𝑂 𝒫  since it requires only one pass over the set 𝒫. The 
complexity of Step 3.a is 𝑂 ℛ . Therefore, the complexity is 𝑂 𝒫 ℛ .  ∎ 
Note that, since 𝛥! depends on both 𝛥! and 𝑛!, we must scan the entire set of ℛ for each 
value of 𝛥! as it is possible to have multiple 𝛥! ,𝑛!  pairs that satisfy the Revenue 
Neutrality Condition. 
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APPENDIX 2 
Design of the Study, TECC Timeline, and PAM Questions  
Design of the Study  
The Institutional Review Boards (IRBs) of the sponsoring hospital system and the host 
university approved the following design during their October 2010 and January 2011 
reviews, respectively.  
 To assess the effect of TECC on reducing readmissions, subjects discharged with 
either Congestive Heart Failure (CHF) and/or Chronic Obstructive Pulmonary Disease 
(COPD) were randomized into two unblinded study groups at each hospital in the system 
following a randomized block design. (See Figure A.1 for details on the randomization 
process and outcome.)  Case managers, discharge planners and research coordinators 
from the nine participating hospitals approached potential patients during their hospital 
discharge process from December 2010 through December 2012.  We excluded patients 
who were: under age 18, discharged to a long-term care facility, referred to a home 
healthcare agency, on dialysis, pregnant, terminally ill, undergoing cancer treatment, had 
dementia, or could not understand English. As shown in Table A.1, there were no 
statistical differences between the control group and the intervention group in regard to 
age, race, or health status, however, there was a higher percentage of women in the 
intervention group (59.5%) versus the control group (45.3%). 	  
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Figure A.1: Randomization process and outcome 
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Table A.1: Patient characteristics of intervention and control groups 
CHARACTERISTIC 
Intervention 
Group 
(n= 74 ) 
Control 
Group 
(n=95 ) 
p-value 
Age – years 60.1 58.8 0.23 
Female – number (%) 44 (59.5%) 43 (45.3%) 0.07 
African – number (%)  0 (0.0%) 1 (1.1%) 0.32 
African American – number (%) 21 (28.4%) 37 (38.9%) 0.15 
Caucasian – number (%) 19 (25.7%) 25 (26.3%) 0.93 
Latino – number (%) 1 (1.4%) 0 (0.0%) 0.32 
Unknown – number (%) 33 (44.6%) 32 (33.7%) 0.15 
CHF 41 (55.4%) 43 (45.3%) 0.19 
Charlson Score 3.43 3.28 0.62 
Modified Charlson Score 4.59 4.43 0.63 
 
 Through the randomization process, we recruited 193 patients who voluntarily 
consented to the process. Using a simple randomization designed to give each patient a 
50 percent probability to be placed in either the control or intervention group 
(specifically, we used computer generated numbers), 93 patients were randomized into 
the intervention group and 100 were randomized to the control group. However, some 
patients were deemed ineligible after the enrollment process, leaving 74 in the 
intervention group and 95 in the control group. Five patients did not complete the full 
intervention and the remaining 69 completed the entire intervention.  
  Patients in both the control and intervention groups were asked to complete a 
PAM survey at the end of the study. From our intervention group of 74 patients, 69 
(93.2%) completed the PAM survey; from our control group of 95 patients, 49 (51.6%) 
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completed the PAM survey. This difference is significant (p<0.001), and shows possible 
attrition bias.  Unfortunately, attrition bias occurs frequently with longitudinal 
experiments, and often the control group feels no obligation to complete the survey, as 
they felt no benefit from the experiment (Hausman & Wise, 1979; Shadish et al. 2002).  
To show this attrition does not affect the validity of our results, we compare the two 
groups’ willingness to change values to show similarity of the groups.  Our intervention 
group has an average willingness to change of -0.48 (sd=0.94), versus our control group 
had an average willingness to change value of -0.54 (sd=1.04). There is no statistical 
difference between the two (p=0.761), thus supporting the underlying similarity of the 
two groups.  
  Subjects assigned to the intervention study group received an Intel Health Guide 
personal health telemonitoring device (Intel 2016) for the 30-day post-discharge period.  
The patients used the device for a variety of daily health management functions: daily 
bio-metric readings, daily health sessions specific to the subject’s health needs, 
educational videos, tracking of appointments, access to medical contacts, and 
videoconferencing with Registered Nurses as scheduled. All medical content associated 
with the telemonitoring device was based on standard practice guidelines. The nurses and 
patients followed the following timeline. This timeline is a guideline and a day or two 
and the exact nature of each called differed depending on patient needs moved some 
teleconferences. 
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Time Line 
On days 1 – 30, the patient used the telemonitoring equipment to track biometrics and 
answer health questions and a nurse reviewed every patient’s data, looking for 
aberrations in results.  These two activities (from the patient side and the nurse side) were 
conducted independently.  In addition to this standard daily monitoring, the following 
events occurred throughout the 30-day period. 
Day 1 
• Telemonitoring equipment delivered to home and installed by contractor 
• Telemonitoring equipment tested by contractor 
• Patient uses telemonitoring equipment to track biometrics (blood pressure, 
weight, etc.) and to answer health questions  
Day 2  
• Patient and nurse participate in video conference and discuss the following: 
o Medication reconciliation 
o Comfort of process with completing health session 
o Follow up issues from previous day 
o Inquiries about follow up appointments needed and assist with scheduling 
as needed 
o Answers questions 
o Schedules another video conference for Day 4 
Day 4 
• Patient and nurse participate in video conference and nurse provides the 
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following:  
o Reassurance and guidance as needed 
o Schedules video conference with patient for Day 7 
Day 7 
• Patient and nurse participate in video conference and nurse provides the 
following:  
o Reassurance and guidance as needed 
o Schedules video conference with patient for Day 10 
Day 10 
• Patient and nurse participate in video conference and nurse provides the 
following:  
o Reassurance and guidance as needed 
o Schedules video conference with patient for Day 12 
Day 12 
• Patient and nurse participate in video conference and nurse provides the 
following:  
o Reassurance and guidance as needed 
o Schedules video conference with patient for Day 19 
Day 19 
• Patient and nurse participate in video conference and nurse provides the 
following:  
o Reassurance and guidance as needed 
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o Schedules video conference with patient for Day 19 
Day 25 
• Nurse schedules device pick up date/time with Equipment Services organization 
• Nurse Informs patient of scheduled date/time for equipment pick up and post on 
Health Guide 
Day 31 to 33 
• Device and equipment picked up from patient home by Equipment Services 
organization which: 
o Examines equipment condition 
o Eliminates all patient information and data on the Health Guide device 
o Re-images Health Guide 
o Sterilizes equipment for reuse  
 After 30 days post-discharge, a single project manager administered the Patient 
Activation Measure™ (PAM) to subjects in both the intervention and control study 
groups. The PAM is a validated and reliable 13-item scale developed by Hibbard et al. 
(2005) widely used to segment patients into levels of activation associated with a variety 
of self-care attitudes and behaviors. Per Hibbard and Cunningham (2008), we converted 
patient’s Patient Activation scores to Patient Activation Levels using the following 
categorizations:  Level 1: scores < 47; Level 2:  scores between 47.1 and 55.1; Level 3: 
scores between 55.2 and 67; Level 4: scores > 67. At the conclusion of our study, our 
intervention group had average scores of 66.9 (standard deviation = 17.3) and our control 
group had average scores of 56.1 (standard deviation = 13.2). 
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PAM Questions  
The following questions are including in the PAM, developed by Hibbard et al (2005). 
Due to the proprietary nature of the instrument, scoring scales are not included. 
1. When all is said and done, I am the person who is responsible for managing my 
health condition. 
2. Taking an active role in my own health care is the most important factor in 
determining my health and ability to function. 
3. I am confident that I can take actions that will help prevent or minimize some 
symptoms or problems associated with my health condition. 
4. I know what each of my prescribed medications does. 
5. I am confident that I can tell when I need to go get medical care and when I can 
handle a health problem myself. 
6. I am confident I can tell my health care provider concerns I have even when he or she 
does not ask. 
7. I am confident that I can follow through on medical treatments I need to do at home. 
8. I understand the nature and causes of my health condition(s). 
9. I know the different medical treatment options available for my health condition. 
10. I have been able to maintain the lifestyle changes for my health that I have made. 
11. I know how to prevent further problems with my health condition. 
12. I am confident I can figure out solutions when new situations or problems arise with 
my health condition. 
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13. I am confident that I can maintain lifestyle changes like diet and exercise even during 
times of stress. 
Technology Implementation 
For all patients who used telemonitoring equipment, an independent contractor delivered 
the following telemonitoring equipment (shown in Figure A.2) to the patients’ homes: 
• One wireless mobile device with video teleconference capabilities 
• Peripheral equipment including a tethered blood pressure cuff 
• One Bluetooth enabled digital scale 
• One Bluetooth pulse oximeter 
The contractor ensured the equipment was working properly and connected for the first 
video conferencing consult with the nurse. The telemonitoring lasted for thirty days.  At 
the end of the telemonitoring period, the same independent contractor then removed the 
equipment from the home. 
 
Figure A.2:  Patient using Healthguide telemonitoring equipment to take blood pressure 
reading.   
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Continuity of Care Procedures  
 Patients used the telemonitoring device to record and transmit their daily vitals: 
weight, blood pressure, pulse oximeter readings, and, for diabetic patients, their 
glucometer readings. They completed this step independently, i.e. without prompts from 
their healthcare provider, and did this using the Intel Healthguide telemonitoring 
equipment.  
 In addition to sharing vitals, patients answered questions daily about their health 
using the telemonitoring device. The questions varied depending on the patient’s overall 
health and length of time post-discharge. Branching logic also allowed for questions to 
vary based on earlier responses. Some representative questions include: a) Are you 
feeling more short of breath than usual today? b) Are you feeling more tired than usual, 
or having more difficulty with routine activities? c) Have you noticed any increased 
swelling in your ankles, feet, legs, or waistline? d) How well have you been able to 
follow a low salt diet in the past week? 
A nurse monitored patients’ responses (both to health questions and vital signs, 
such as blood pressure) daily.  If a patients’ readings were out of the normal range, a 
nurse would contact the patient.  For high severity symptoms, nurses would coach the 
patient to contact their physician or proceed to the emergency room. For low severity 
symptoms, the nurse would seek to understand the cause and then initiate a discussion 
linking patient choices with their symptoms. This early warning system provided nurses 
with the means to recognize potential problems and intervene, as concerning 
questionnaire responses often preceded vital sign changes, therefore this additional 
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telemonitoring activity gave the nurse and patient another means to recognize detrimental 
changes in the patient’s condition.  
Comparison between Logistic Regression and Linear Support Vector Machines 
 There are multiple criteria for contrasting the properties of Logistic Regression 
and Linear Support Vector Machines. These are summarized in Table A.2 and supporting 
arguments are discussed below the table. These arguments are drawn from Cortes and 
Vapnik (1995), Burgess (1998) and Bishop (2006). Based on this comparison, we have 
determined that the total percentage error is the relevant criteria for selecting the 
prediction model (i.e. Linear Support Vector Machine instead of Logistic Regression) in 
our analysis.   
Results from Logistic Regression provide a probability of a data point belonging 
to a certain group. On the other hand, linear SVM simply divides data points into one 
group or another.   
 Logistic Regression uses all points to determine probabilities of classification, 
including outliers.  SVM only uses data points closest to the hyperplane, which separates 
two groups.  This allows the SVM algorithm to ignore outliers and possibly avoid skewed 
results. An important difference is that SVM only needs the points closest to the 
hyperplane (or support vectors). This means that any other point will always be classified 
correctly, independently of whether or not they are in the training set.  The more support 
vectors used, the higher the likelihood of a misclassification, as more points are needed to 
ensure a correct classification. In this way, SVM is able to provide higher precision in 
prediction, with a small data set, when compared with the logistic regression model.   
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Table A.2: Comparison between Logistic Regression and Support Vector Machines  
Category Logistic Regression 
Linear Support Vector 
Machines (SVM) 
1. Type of classifier Probabilistic Classifier 
Non-probabilistic binary 
linear classifier 
2. Data points considered Considers all data points 
Only considers data points 
near the margin 
3. Impact of the 
independent variable 
Regression coefficients, 
with p-value, indicate the 
impact of relationship 
between the dependent 
variable and the 
independent variable  
Feature weights indicate 
how important an 
independent variable is in 
creating the separation 
between two classes, 
independent of sign.  
4. Use of Null Hypotheses Use null hypotheses  
The idea of null 
hypothesis is not relevant. 
The goal is to establish a 
classification boundary 
5. Treatment of selection 
bias 
Hard to remove selection 
bias 
Hard Classifier: No 
selection bias 
6. Classifications of Error 
Outcome includes a total 
number of errors 
produced, including both 
the amount of Type I and 
Type II error 
Outcome includes a total 
number of errors 
produced, including both 
the amount of Type I and 
Type II error 
   
 Logistic Regression output provides regression coefficients that represent the 
relative impact of each independent variable.  Additionally, p-values associated with each 
regression coefficient indicate the probability that the regression coefficient is different 
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from 0.  Independent variables with larger absolute values of regression coefficients and 
with smaller p-values indicate those variables (ceteris paribus) will have a bigger impact 
on the dependent variable. Regression coefficients can have either positive or negative 
values and will impact the dependent variable accordingly.  On the other hand, the signs 
of support vector machine feature weights have no effect on the dependent variable. Only 
the magnitude of the feature weights is relevant, and these weights have no p-value 
associated with them.  Similar to regression coefficients, a larger value feature weight 
associated with an independent variable means a change in that independent variable will 
have a larger impact on the dependent variable.    
 Because regression coefficients have p-values associated with them, they can be 
used to test the null hypothesis – i.e. whether or not that value is different from zero.  
Conversely, the null hypothesis cannot be tested with linear SVM because there is no p-
value associated with feature weights.   
 Logistic Regression does not provide a way to remove selection bias.  On the 
other hand, in SVM analysis, there is no systematic selection bias, as a constraint 
associated with the objective function of a linear classifier is that all data points in the 
training set must be classified correctly (Zadrozny 2004). 
 Finally, both Logistic Regression and SVM produce outcomes such as total 
number of errors, total error percentage, and the amount of Type I and Type II error. 
These allow assessment of their predictive power.  Since one can calculate these error 
rates for both methodologies, one can compare the effectiveness of the two 
methodologies.   
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Logistic Regressions  
For the regression analysis, the prediction outcome (dependent variable) was whether the 
patient belonged in the lower category (e.g., Level 1) or the higher category (e.g., Level 
2,3, and 4), based on the known patient characteristics (independent variables): whether 
they had TECC and a high willingness to change or a low willingness to change.   
 In order to compare with the SVM results, we analyzed the logistic regression 
model using a training size of 45. Table A.3 shows that none of the regression 
coefficients are significant. Comparing Table A.4 in this document versus 4B within the 
main manuscript, we see that for a training set size of 45, we have lower total error 
percentages and lower Type I and Type II errors for the SVM analysis versus the Logistic 
regression analysis. 
 
 Table A.3: Linear Regression: Regression Coefficients and Pseudo R2  
 
Level 1 v. 2,3,4 Levels 1,2 v. 3,4 Levels 1,2,3 v. 4 
TECC* -1.088 -0.794 -0.684 
Low Willingness* 2.046 0.915 0.067 
High Willingness* 0.604 0.118 0.437 
Pseudo R2 0.217 0.196 -0.130 
*None of the regression coefficients are significant to a p<0.1. 	  
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Table A.4: Errors associated with Logistic regression 
 
Level 1 v. 2,3,4 Levels 1,2 v. 3,4 Levels 1,2,3 v. 4 
Total Error* (%) 14.0 34.8 30.5 
Type I Error (%) 11.8 27.8 35.8 
Type II Error (%) 26.7 38.2 26.3 
Detection Bias -7.5 -5.2 4.8 
*Where the total error percentage is defined as the number of incorrect predictions divided by the total 
number of predictions. 
Comparison of Cross Validation Losses between Linear, Gaussian, and Polynomial 
Support Vector Machines 
In order to decide which type of Support Vector Machine we should utilize for our 
prediction of a patient’s PAM level, we compared a Linear, Gaussian, and 2nd-Order 
Polynomial Support Vector Machines for all 7 potential training set sizes.  After running 
100 iterations of our algorithm, we found that the average cross validation losses, 
expressed as percentages, across all three classification boundaries for both Non-Linear 
Support Vector Machines were higher than for the Linear Support Vector Machine by at 
least 1%. Thus, we chose to use the Linear SVM. 	  
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Table A.5:  Comparison of K-Fold Cross Validation Losses (%) between Linear, Gaussian, 
and Polynomial Support Vector Machines 
Training Set Size Linear SVM Gaussian SVM Polynomial SVM 
30 25.6 26.5 45.0 
35 25.6 26.4 45.4 
40 24.6 25.9 44.4 
45 24.5 25.4 44.7 
50 25.1 26.0 46.6 
55 24.6 26.1 47.8 
60 25.0 26.4 46.2 
 
Cross Validation Loss for SVM Estimator 
In order to choose the ideal training set size to train our support vector machine, we 
looked at the cross validation loss for the estimator, both the k-fold loss and the leave-
one-out-loss, and both showed us that a training set size of 45 produced the lowest cross 
validation error. Thus, we decided to use a training set size of 45. 
 	  
		
131 
Table A.6: Comparison of Leave-One-Out and K-Fold Cross Validation Errors  
Training Set Size K-Fold Cross 
Validation Error (%) 
Leave-One-Out Cross 
Validation Loss (%) 
30 25.6 25.6 
35 25.6 25.2 
40 24.6 25.4 
45 24.5 23.7 
50 25.1 25.4 
55 24.6 24.1 
60 25.0 25.3 
 
Multinomial Logistic Regression and Multi-Class Support Vector Machine Models 
In addition to considering logistic regression and linear support vector machines, we 
considered a multi-class SVM. First, we compared the K-Fold Cross Validation Losses 
for the linear versus multi-class SVM.  We show these results in Table A.7. Then, we 
compared a multinomial logistic regression model to other classifiers (see Table A.8). 	  
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Table A.7: Comparison of K-Fold Cross Validation Errors (%) for Linear SVM versus 
Multi-Class SVM 
Training Set Size Linear SVM* Multi-Class SVM 
30 25.6 59.4 
35 25.6 60.7 
40 24.6 64.2 
45 24.5 65.2 
50 25.1 65.3 
55 24.6 65.2 
60 25.0 62.9 
* Also reported in Table A.6 Column 2 
 We found that neither for multinomial logistic regression nor the multi-class support 
vector machines provide an improvement in the total error, and in both cases, the average 
total prediction error increased (See Table A.8). One explanation for this larger error rate 
is that a multi-class SVM and multinomial SVM setups are carried out using smaller 
training set size, owing to heterogeneous sample sizes for activation levels, than three 
separate SVMs. This further enforced our belief that we made the appropriate choice of 
choosing to use a linear support vector machine to make our predictions. 	  
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Table A.8: Comparison of Average Total Errors for Training Set Size of N=45 
Classifier Average Total Error (%) 
Linear SVM 24.7 
Multi-Class SVM 64.2 
Logistic Regression 26.4 
Multinomial Logistic Regression 63.7 
 
Receiver Operating Characteristic 
  In order to look at the performance for each of our three binary classifiers, we 
examined the Receiver Operating Characteristic (ROC) curves as shown in Figure A.3.  
The area under the curve (AUC) illustrates the probability that a binary classifier will 
perform better that randomly assigning data points to different classes.  This means that 
the classifier needs to perform better than an outcome of 0.5, with the best classifier 
being closer to 1. Thus, the first classifier (Level 1 v. Levels 2,3,4) has higher 
discriminatory power than the classifier for Levels 1,2 v. Levels 3,4.  And the Levels 1,2 
v. Levels 3,4 classifier has higher discriminatory power than that for Levels 1,2,3 v. 4 
(Hajian-Tilaki 2013). 	  
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Table A.9: Comparison of AUC Values for Different Classification Boundaries  
 
Level 1 v. 2,3,4 Levels 1,2 v. 3,4 Levels 1,2,3 v. 4 
AUC 0.724 0.682 0.660 
 
Table A.10: Comparison of True Positive Rates (TPR) and False Positive Rates (FPR) for 
Different Classification Boundaries  
 
Level 1 v. 2,3,4 Levels 1,2 v. 3,4 Levels 1,2,3 v. 4 
FPR (%) 4.18 48.3 49.6 
TPR (%) 62.1 64.9 61.9 
FPR/TPR 67.4 74.4 80.1 
 
Figure A.3: Receiver Operating Curve 
 
False Positive Rate
0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1
Tr
ue
 P
os
iti
ve
 R
ate
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
Level 1 v Level 2,3,4
Level 1,2 v Level 3,4
Level 1,2,3 v Level 4
		
135 
Bootstrapping for Prediction of Activation Levels based on the different 
Independent Variables 
 We performed a bootstrapping analysis, where we decided to look at the 
prediction of the different classification boundaries based on the different independent 
variables that we used in our prediction model: TECC, Low Willingness to Change, and 
High Willingness to Change.  
 The results show only one combination where the entire confidence interval is 
positive, which is indicative of a non-accidental relationship between the patient 
activation measure scores and readmission. The confidence intervals associated with the 
TECC variable are all positive, meaning there is a strong association with TECC at each 
classification boundary. This finding is understandable, as it is associated with the 
predictor variable that has the strongest association with each divide according to its 
feature weight (as shown in Table 8A in the main manuscript). This simulation confirms 
that by combining the three variables in our prediction model, we have reported a robust 
PAM prediction, however, individually none of these variable have the requisite 
predictive power. 
Table A.11: Bootstrapping Confidence Intervals 
 Level 1 v. 2,3,4 Levels 1,2 v. 3,4 Levels 1,2,3 v. 4 
TECC [0.047, 0.395] [0.136,0.482] [0.058, 0.373] 
Low Willingness to Change [-0.064,0.291] [-0.132,0.240] [-0.149,0.208] 
High Willingness to Change [-0.271,0.117] [-0.142,0.210] [-0.243,0.108] 
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